<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40007016</article-id><article-id pub-id-type="pmc">PMC11860675</article-id><article-id pub-id-type="doi">10.3390/v17020261</article-id><article-id pub-id-type="publisher-id">viruses-17-00261</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Neuropathogenesis of Old World Alphaviruses: Considerations for the Development of Medical Countermeasures</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5231-0009</contrib-id><name><surname>Lantz</surname><given-names>Alyssa M.</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0916-360X</contrib-id><name><surname>Baxter</surname><given-names>Victoria K.</given-names></name><xref rid="c1-viruses-17-00261" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>de Oliveira Fran&#x000e7;a</surname><given-names>Rafael Freitas</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Stabeli</surname><given-names>Rodrigo</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Pereira</surname><given-names>Mylena R.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00261">Texas Biomedical Research Institute, San Antonio, TX 78227, USA; <email>alantz@txbiomed.org</email></aff><author-notes><corresp id="c1-viruses-17-00261"><label>*</label>Correspondence: <email>vbaxter@txbiomed.org</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>261</elocation-id><history><date date-type="received"><day>17</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>08</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Chikungunya virus (CHIKV) and other alphaviruses that primarily induce arthritogenic disease in humans, known as &#x0201c;Old World&#x0201d; alphaviruses, present an emerging public health concern as geographic ranges of mosquito vectors expand due to climate change. While a vaccine against CHIKV has recently been approved by several countries in North America and Europe, access to effective preventative countermeasures against disease induced by Old World alphaviruses remains elusive for the most vulnerable populations. Furthermore, treatment options continue to be limited to supportive care. Atypical neurological disease manifestations caused by Old World alphaviruses, which make up as many as 25% of the cases in some CHIKV outbreaks, present special challenges when considering strategies for developing effective countermeasures. This review focuses on Old World alphaviruses, specifically CHIKV, Ross River virus, O&#x02019;nyoug-nyoug virus, and Mayaro virus, concentrating on the atypical neurological disease manifestations they may cause. Our current understanding of Old World alphavirus neuropathogenesis, gained from human cases and preclinical animal models, is discussed, including viral and host factors&#x02019; roles in disease development. The current state of alphavirus preventatives and treatments, both virus-targeting and host-directed therapies, is then summarized and discussed in the context of addressing neurological disease induced by Old World alphaviruses.</p></abstract><kwd-group><kwd>Old World alphaviruses</kwd><kwd>chikungunya virus</kwd><kwd>neuropathogenesis</kwd><kwd>neurological disease</kwd><kwd>vaccines</kwd><kwd>treatments</kwd></kwd-group><funding-group><award-group><funding-source>National Institute of Neurological Disorders and Stroke</funding-source><award-id>R21NS135258</award-id></award-group><funding-statement>The work was supported by National Institute of Neurological Disorders and Stroke grant number R21NS135258.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00261"><title>1. Introduction</title><p>Alphaviruses are positive-sense, single-stranded RNA viruses in the <italic toggle="yes">Togaviridae</italic> family. Most clinically important alphaviruses are transmitted by mosquitoes. Due to mosquito vectors expanding to new geographical regions, alphaviruses represent a re-emerging public health concern [<xref rid="B1-viruses-17-00261" ref-type="bibr">1</xref>,<xref rid="B2-viruses-17-00261" ref-type="bibr">2</xref>,<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>]. In particular, the alphavirus chikungunya virus (CHIKV) has been declared a high-risk threat to public health, as the geographic extent of its primary vectors, <italic toggle="yes">Aedes aegypti</italic> and <italic toggle="yes">Aedes albopictus</italic>, has increased as global temperatures have risen [<xref rid="B4-viruses-17-00261" ref-type="bibr">4</xref>]. Reports of CHIKV cases and deaths have increased four-fold from 2022 to 2023 [<xref rid="B2-viruses-17-00261" ref-type="bibr">2</xref>]; however, these statistics are likely underestimated due to inconsistent, inadequate surveillance and misdiagnosis [<xref rid="B4-viruses-17-00261" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-00261" ref-type="bibr">5</xref>].</p><p>Alphaviruses are traditionally categorized as &#x0201c;New World&#x0201d; or &#x0201c;Old World&#x0201d; based on historical geographical origins and correlate with natural disease typically induced in humans [<xref rid="B6-viruses-17-00261" ref-type="bibr">6</xref>]. New World alphaviruses, which include eastern equine encephalitis virus, western equine encephalitis virus, and Venezuelan equine encephalitis virus, typically induce neurological disease and pathology. Old World alphaviruses, in addition to CHIKV, include, but are not limited to, Ross River virus (RRV) [<xref rid="B7-viruses-17-00261" ref-type="bibr">7</xref>], O&#x02019;nyoug-nyoug virus (ONNV) [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>], and Mayaro virus (MAYV) [<xref rid="B8-viruses-17-00261" ref-type="bibr">8</xref>,<xref rid="B9-viruses-17-00261" ref-type="bibr">9</xref>]. These alphaviruses tend to cause a more systemic disease characterized by headache, fever, and malaise, along with arthritis and arthralgia [<xref rid="B10-viruses-17-00261" ref-type="bibr">10</xref>]. However, Old World alphavirus infection may also result in neurological disease and pathology depending on the virus.</p><p>Understanding the pathogenesis of alphaviruses is critical to developing effective countermeasures. Here, we review the host and viral factors&#x02019; roles in Old World alphavirus pathogenesis, specifically focusing on atypical neurological disease manifestations. We also discuss how the nature of neurological disease induced by Old World alphaviruses presents additional challenges when designing treatment strategies.</p></sec><sec id="sec2-viruses-17-00261"><title>2. Neurological Disease Induced by Old World Alphaviruses</title><sec id="sec2dot1-viruses-17-00261"><title>2.1. Epidemiology and Vectors</title><p>CHIKV was one of the first isolated Old World alphaviruses identified to cause clinical disease in humans [<xref rid="B11-viruses-17-00261" ref-type="bibr">11</xref>]. CHIKV was first identified in 1952 in Tanzania [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>]. For half a century following the first large outbreak in 1952, CHIKV was limited to occasional outbreaks in Africa and Asia [<xref rid="B13-viruses-17-00261" ref-type="bibr">13</xref>]. However, CHIKV evolved and adapted to a new vector, resulting in a large-scale outbreak in islands across the Indian Ocean, including La R&#x000e9;union, Seychelles, Mauritius, Madagascar, and Mayotte in 2005&#x02013;2006 [<xref rid="B14-viruses-17-00261" ref-type="bibr">14</xref>]. Three phylogenetic lineages of CHIKV have now been identified: East, Central, and South African (ECSA), West African, and Asian. As of 2024, CHIKV has spread globally, with over 3.7 million cases reported in the Americas over the last decade, including the United States [<xref rid="B13-viruses-17-00261" ref-type="bibr">13</xref>]; an additional few cases have been documented in Europe.</p><p>ONNV and MAYV are Old World alphaviruses that, thus far, are relatively limited geographically. ONNV was first isolated during an epidemic in 1959 in Uganda [<xref rid="B15-viruses-17-00261" ref-type="bibr">15</xref>], during which over 2 million cases were reported over three years. Since then, the virus has spread across Central, East, and West Africa but has not been identified outside of the African continent, except for some imported cases in Canada and Germany [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>]. However, the number of cases is likely under-represented. A close evolutionary relationship exists between CHIKV and ONNV [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>], with 89% genome conservation [<xref rid="B16-viruses-17-00261" ref-type="bibr">16</xref>]. MAYV was first identified in five patients with febrile illness in Trinidad and Tobago in 1954 [<xref rid="B17-viruses-17-00261" ref-type="bibr">17</xref>]. Since then, outbreaks have been restricted to Central and South America, usually in tropical rainforests [<xref rid="B9-viruses-17-00261" ref-type="bibr">9</xref>]. Imported cases have been identified in non-forested areas, including North America and Europe [<xref rid="B18-viruses-17-00261" ref-type="bibr">18</xref>]. As it is transmitted by the same vector as CHIKV, possible urbanization of MAYV presents an emerging public health concern [<xref rid="B9-viruses-17-00261" ref-type="bibr">9</xref>,<xref rid="B18-viruses-17-00261" ref-type="bibr">18</xref>,<xref rid="B19-viruses-17-00261" ref-type="bibr">19</xref>].</p><p>RRV is one of the most common arboviruses in Australia [<xref rid="B20-viruses-17-00261" ref-type="bibr">20</xref>,<xref rid="B21-viruses-17-00261" ref-type="bibr">21</xref>]. It was first isolated in mosquitoes in Queensland, Australia, in the 1950s and was first isolated from humans in the early 1970s [<xref rid="B20-viruses-17-00261" ref-type="bibr">20</xref>,<xref rid="B22-viruses-17-00261" ref-type="bibr">22</xref>]. The primary reservoir host is marsupials, specifically kangaroos and wallabies [<xref rid="B20-viruses-17-00261" ref-type="bibr">20</xref>,<xref rid="B23-viruses-17-00261" ref-type="bibr">23</xref>,<xref rid="B24-viruses-17-00261" ref-type="bibr">24</xref>,<xref rid="B25-viruses-17-00261" ref-type="bibr">25</xref>]; however, some evidence suggests human-to-human transmission can occur without an intermediate mosquito host, though this finding is not conclusive [<xref rid="B26-viruses-17-00261" ref-type="bibr">26</xref>]. RRV is endemic in Australia and Papua New Guinea but has been detected elsewhere, including French Polynesia and American Samoa [<xref rid="B7-viruses-17-00261" ref-type="bibr">7</xref>].</p><p>Other Old World alphaviruses, including Sindbis virus (SINV) and Semliki forest virus (SFV), generally are considered non-pathogenic but have been associated with sporadic cases of fever, myalgia, and arthralgia [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>]. SINV is widespread through Europe, Asia, and Africa, but most cases in humans are reported in Scandia and caused by Ockelbo, Pogosta, or Karelin SINV strains [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>,<xref rid="B26-viruses-17-00261" ref-type="bibr">26</xref>]. SFV is also usually non-pathogenic in humans, causing mild fever and arthralgia, but a case of laboratory-acquired SFV infection leading to fatal encephalitis has been reported [<xref rid="B27-viruses-17-00261" ref-type="bibr">27</xref>,<xref rid="B28-viruses-17-00261" ref-type="bibr">28</xref>]. These alphaviruses are commonly used as models for alphavirus neuropathogenesis in mice and will be discussed later in the review [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>].</p><p>Old World alphaviruses typically maintain a sylvatic cycle, transferring between mosquito vectors and vertebrate hosts [<xref rid="B29-viruses-17-00261" ref-type="bibr">29</xref>]. However, transmission from indiscriminate mosquitoes to humans occasionally occurs, and in more extreme situations, such as seen with CHIKV, a second urban cycle between mosquitoes and humans is established. The primary vector of CHIKV in urban areas is <italic toggle="yes">Ae. aegypti</italic> [<xref rid="B30-viruses-17-00261" ref-type="bibr">30</xref>]. However, in the early 2000s, a mutation (E1 A226V) identified during an ECSA-lineage outbreak in the Indian Ocean led to the virus adapting to <italic toggle="yes">A. albopictus</italic> [<xref rid="B14-viruses-17-00261" ref-type="bibr">14</xref>,<xref rid="B31-viruses-17-00261" ref-type="bibr">31</xref>]. ONNV is unique compared to other alphaviruses as it is transmitted by <italic toggle="yes">Anopheles</italic> mosquito species, which are vectors of <italic toggle="yes">Plasmodium</italic> spp. that cause malaria [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>]. Arboreal <italic toggle="yes">Haemagogus janthinomys</italic> mosquitoes primarily transmit MAYV, but urbanization of this virus is possible, as <italic toggle="yes">Ae. aegypti</italic> can also transmit MAYV [<xref rid="B9-viruses-17-00261" ref-type="bibr">9</xref>,<xref rid="B18-viruses-17-00261" ref-type="bibr">18</xref>,<xref rid="B19-viruses-17-00261" ref-type="bibr">19</xref>]. One case in Haiti involving an 8-year-old boy showed co-infection of dengue virus (DENV) and MAYV [<xref rid="B32-viruses-17-00261" ref-type="bibr">32</xref>], which suggests that <italic toggle="yes">Ae. aegypti</italic> may have been the mosquito vector. RRV is considered a vector generalist, as it can be transmitted by over 40 species of mosquitoes [<xref rid="B7-viruses-17-00261" ref-type="bibr">7</xref>,<xref rid="B19-viruses-17-00261" ref-type="bibr">19</xref>,<xref rid="B33-viruses-17-00261" ref-type="bibr">33</xref>], including <italic toggle="yes">Ae. aegypti</italic> and <italic toggle="yes">Ae. albopictus</italic>. With the expansion of mosquitoes and the rise in global temperature, it is plausible for RRV to spread worldwide.</p></sec><sec id="sec2dot2-viruses-17-00261"><title>2.2. Neurological Disease Manifestations and Sequelae</title><p>CHIKV, ONNV, MAYV, and RRV are a part of the Semliki Forest virus complex and induce similar disease manifestations. Typical acute Old World alphavirus infections are self-limiting and characterized by fever, polyarthralgia, myalgia, and rash, with significant symptom overlap [<xref rid="B10-viruses-17-00261" ref-type="bibr">10</xref>]. Small joints of the extremities, including hands, wrists, fingers, and knees, are most likely to be affected. Following acute infection, patients can develop chronic arthritic symptoms that can last months to years following initial infection [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>,<xref rid="B18-viruses-17-00261" ref-type="bibr">18</xref>,<xref rid="B34-viruses-17-00261" ref-type="bibr">34</xref>,<xref rid="B35-viruses-17-00261" ref-type="bibr">35</xref>]. Some persistent symptoms include fatigue, joint tenderness, joint and muscle pain, and musculoskeletal stiffness [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>]. However, atypical neurological sequelae are described following infection with some of these viruses, especially CHIKV. <xref rid="viruses-17-00261-t001" ref-type="table">Table 1</xref> summarizes case reports of neurological disease currently for Old World alphaviruses.</p><p>Between 7 and 25% of CHIKV cases during outbreaks have been reported to include neurological disease symptoms [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>,<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>,<xref rid="B48-viruses-17-00261" ref-type="bibr">48</xref>,<xref rid="B49-viruses-17-00261" ref-type="bibr">49</xref>]. Of the three phylogenetic CHIKV clades, ECSA strains have been more closely associated with neurological symptoms [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>,<xref rid="B50-viruses-17-00261" ref-type="bibr">50</xref>]. However, neurovirulence has also been reported in individuals infected with Asian strains [<xref rid="B50-viruses-17-00261" ref-type="bibr">50</xref>], and genotyping is rarely done in clinical settings to distinguish strains from different phylogenetic lineages. Encephalitis and peripheral neuropathologic conditions such as Guillain&#x02013;Barre syndrome (GBS) are the most commonly reported neurological disease manifestations [<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>,<xref rid="B49-viruses-17-00261" ref-type="bibr">49</xref>]. Pathological changes in the central nervous system (CNS) tissue include perivascular and parenchymal infiltration of mononuclear cells, microgliosis, and demyelinating lesions [<xref rid="B41-viruses-17-00261" ref-type="bibr">41</xref>,<xref rid="B51-viruses-17-00261" ref-type="bibr">51</xref>,<xref rid="B52-viruses-17-00261" ref-type="bibr">52</xref>]. Survivors of the initial course of neurological disease are often left with permanent neurological sequelae that result in significant lifelong disability [<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>,<xref rid="B48-viruses-17-00261" ref-type="bibr">48</xref>,<xref rid="B53-viruses-17-00261" ref-type="bibr">53</xref>].</p><p>ONNV typically induces a clinical disease similar to CHIKV infection, though without acute edema in joints [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>,<xref rid="B54-viruses-17-00261" ref-type="bibr">54</xref>]. No known neurological complications have been associated with ONNV infection [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>], but in vitro studies have shown Schwann cells are permissive to infection, and A129 and <italic toggle="yes">Stat1<sup>&#x02212;/&#x02212;</sup></italic> mice are susceptible to occasional neuroinvasion [<xref rid="B55-viruses-17-00261" ref-type="bibr">55</xref>]. MAYV manifests as a non-specific, self-limited acute febrile illness that is often misdiagnosed for DENV or CHIKV; however, fever can last up to ten days, distinguishing the virus from other arboviruses that tend to circulate in the same regions [<xref rid="B9-viruses-17-00261" ref-type="bibr">9</xref>,<xref rid="B18-viruses-17-00261" ref-type="bibr">18</xref>]. MAYV can infect human neural progenitor cells, pericytes, and astrocytes in vitro [<xref rid="B56-viruses-17-00261" ref-type="bibr">56</xref>], and one case of neurological disease has been reported in humans [<xref rid="B45-viruses-17-00261" ref-type="bibr">45</xref>]. A 47-year-old male patient in French Guiana diagnosed with acute meningoencephalitis after a five-day history of frontal headaches, photophobia, meningeal stiffness, fatigue, aphasia, and confusion was positive for MAYV IgM [<xref rid="B45-viruses-17-00261" ref-type="bibr">45</xref>]. Since ONNV and MAYV are genetically similar to CHIKV, both viruses theoretically have the propensity to evolve and induce neurological disease [<xref rid="B57-viruses-17-00261" ref-type="bibr">57</xref>]. However, viral evolution is influenced by many factors, including, but not limited to, cycling between different host species, climate, and vector geographical range [<xref rid="B58-viruses-17-00261" ref-type="bibr">58</xref>]; therefore, it is currently unclear whether these alphaviruses will evolve to induce neurological disease based solely on genetic similarity to CHIKV.</p><p>While most cases of RRV infection are asymptomatic, when present, symptoms include rash, fever, flu-like illness, lethargy, myalgia, arthralgia, and joint stiffness [<xref rid="B20-viruses-17-00261" ref-type="bibr">20</xref>,<xref rid="B33-viruses-17-00261" ref-type="bibr">33</xref>,<xref rid="B59-viruses-17-00261" ref-type="bibr">59</xref>]. Symptoms, mainly arthralgia and joint stiffness, may persist for months past infection, with only 27% of patients in one study recovering fully by six months [<xref rid="B59-viruses-17-00261" ref-type="bibr">59</xref>]. Atypical sequelae have been reported, including neurological manifestations such as encephalitis and meningitis [<xref rid="B33-viruses-17-00261" ref-type="bibr">33</xref>]. However, definitive proof that RRV is responsible for the few reported cases of neurological disease has not been made [<xref rid="B33-viruses-17-00261" ref-type="bibr">33</xref>,<xref rid="B47-viruses-17-00261" ref-type="bibr">47</xref>]. One paper documented a potential imported case where a 33-year-old male had traveled to Australia during an RRV outbreak and was bitten by mosquitoes [<xref rid="B47-viruses-17-00261" ref-type="bibr">47</xref>]. He presented with encephalitis at the hospital in his home country, tested positive for RRV IgM and IgG, and had persistent hip and shoulder pain weeks after discharge, supporting the possibility that RRV also caused his neurological symptoms.</p></sec><sec id="sec2dot3-viruses-17-00261"><title>2.3. Using Animal Models to Study Alphavirus Neuropathogenesis</title><p>The limited accessibility and minimally regenerative nature of the CNS prevent alphavirus neuropathogenesis studies from being performed in humans and require animal models, especially when evaluating disease pathogenesis. CHIKV encephalitis has been studied in multiple animal models, including zebrafish [<xref rid="B60-viruses-17-00261" ref-type="bibr">60</xref>,<xref rid="B61-viruses-17-00261" ref-type="bibr">61</xref>] and macaques [<xref rid="B62-viruses-17-00261" ref-type="bibr">62</xref>,<xref rid="B63-viruses-17-00261" ref-type="bibr">63</xref>]. However, mice are a valuable tool because of their comparable immune system to humans, genetic manipulability, and lower cost than macaques. Several papers investigating CHIKV neuropathogenesis in mouse models have been published [<xref rid="B50-viruses-17-00261" ref-type="bibr">50</xref>,<xref rid="B64-viruses-17-00261" ref-type="bibr">64</xref>,<xref rid="B65-viruses-17-00261" ref-type="bibr">65</xref>,<xref rid="B66-viruses-17-00261" ref-type="bibr">66</xref>,<xref rid="B67-viruses-17-00261" ref-type="bibr">67</xref>,<xref rid="B68-viruses-17-00261" ref-type="bibr">68</xref>]. Most studies have used neonatal or immunocompromised mice, limiting the translatability of the findings to susceptible human populations. Young adult (4&#x02013;6 week old) C57BL/6J (B6) mice have been identified as a potential immunocompetent and neurodevelopmentally appropriate mouse model to study direct CNS infection with CHIKV [<xref rid="B69-viruses-17-00261" ref-type="bibr">69</xref>,<xref rid="B70-viruses-17-00261" ref-type="bibr">70</xref>]; mice in this age range are neurodevelopmentally equivalent to a one- to two-year-old child, an especially vulnerable age for developing neurological disease following alphavirus infection [<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>,<xref rid="B40-viruses-17-00261" ref-type="bibr">40</xref>]. Attempts to achieve CNS infection following peripheral inoculation have generally been unsuccessful in adult B6 mice; however, one group reported successful brain infection following subcutaneous footpad injection with a CHIKV strain isolated from Delhi in 2010 [<xref rid="B71-viruses-17-00261" ref-type="bibr">71</xref>,<xref rid="B72-viruses-17-00261" ref-type="bibr">72</xref>]. While arthritogenic disease pathogenesis and host immune responses have been studied in mouse models for MAYV [<xref rid="B73-viruses-17-00261" ref-type="bibr">73</xref>,<xref rid="B74-viruses-17-00261" ref-type="bibr">74</xref>], ONNV [<xref rid="B55-viruses-17-00261" ref-type="bibr">55</xref>,<xref rid="B75-viruses-17-00261" ref-type="bibr">75</xref>], and RRV [<xref rid="B76-viruses-17-00261" ref-type="bibr">76</xref>,<xref rid="B77-viruses-17-00261" ref-type="bibr">77</xref>], no publications describing animal models of neurological disease induced by any of these viruses have been released to date. However, a paper describing subcutaneous infection of three rhesus macaques with MAYV showed the virus could disseminate to the CNS, though neurological signs were not identified in any of the animals [<xref rid="B78-viruses-17-00261" ref-type="bibr">78</xref>].</p><p>As mentioned previously, while SINV and SFV do not induce significant human disease, particularly neurological complications, from natural infection, these viruses have played an outsized role in understanding neurological disease caused by alphaviruses using mouse models. The naturally occurring SINV strain AR339 can disseminate to the CNS effectively, and a correlation has been found between age and severity of SINV AR339-induced disease, with neonatal mice more susceptible to lethal disease than weanling mice [<xref rid="B79-viruses-17-00261" ref-type="bibr">79</xref>,<xref rid="B80-viruses-17-00261" ref-type="bibr">80</xref>]. SINV has been adapted to be neurotropic in mice, providing a valuable, well-characterized model to study alphavirus encephalomyelitis [<xref rid="B81-viruses-17-00261" ref-type="bibr">81</xref>,<xref rid="B82-viruses-17-00261" ref-type="bibr">82</xref>]. A neuro-adapted SINV strain, NSV, was created by serially passaging the AR339 strain six times in neonatal and weanling mice via intracerebral inoculation [<xref rid="B83-viruses-17-00261" ref-type="bibr">83</xref>]. NSV induces 100% mortality in susceptible mice of all ages [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>,<xref rid="B83-viruses-17-00261" ref-type="bibr">83</xref>]. SINV has been shown to enter the CNS through axonal transport and disseminate throughout the brain and spinal cord, where it infects neurons and can lead to neuronal damage and death [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>].</p><p>While SFV typically causes mild fever, myalgia, and arthralgia in humans, in mouse models, infection induces meningoencephalomyelitis with demyelination [<xref rid="B84-viruses-17-00261" ref-type="bibr">84</xref>,<xref rid="B85-viruses-17-00261" ref-type="bibr">85</xref>]. The avirulent strain A7(74) produces a transient viral infection in mice. While BALB/c mice do not develop clinical disease, severe combined immunodeficiency (SCID) mice develop paralysis and moderate mortality by 5 days post-infection (dpi) [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>,<xref rid="B86-viruses-17-00261" ref-type="bibr">86</xref>]. The virus enters the CNS by infecting vascular endothelial cells [<xref rid="B87-viruses-17-00261" ref-type="bibr">87</xref>], and while SFV can infect neurons, in contrast to SINV, oligodendrocytes represent the primary target cell in the CNS [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>].</p><p>Several approaches, including microarray, RNA sequencing, and candidate gene studies, have been developed in animal models to study different factors that affect alphavirus pathogenesis, particularly host genetics&#x02019; role in disease [<xref rid="B88-viruses-17-00261" ref-type="bibr">88</xref>]. In addition, newer systematic approaches are now being used to understand how heterogeneous populations react to alphavirus infections. One study that screened eight different inbred mouse strains and compared disease severity following SFV intraperitoneal infection found that while all strains developed encephalitis, only three showed definitive signs of demyelination [<xref rid="B89-viruses-17-00261" ref-type="bibr">89</xref>]. Another study comparing BALB/c and B6 mice infected with SINV NSV identified a locus on chromosome 2, Nsv1, associated with viral load, development of paralysis, and death [<xref rid="B88-viruses-17-00261" ref-type="bibr">88</xref>,<xref rid="B90-viruses-17-00261" ref-type="bibr">90</xref>].</p><p>While mouse models have played a critical role in understanding alphavirus neuropathogenesis, their use presents multiple limitations. As discussed above, limited data exist on successful alphavirus neuroinvasion following peripheral infection in adult B6 mice. In most studies, investigators infect mice by intracranial inoculation, which is an unnatural route of infection and limits translation to the natural course of disease in humans. Because alphaviruses are transmitted by mosquitoes through peripheral infection, subcutaneous inoculation represents a more natural route of infection by which to understand mechanisms of neuroinvasion and develop potential medical countermeasures. Furthermore, as described above, the common use of neonatal or immunocompromised mice in alphavirus neuropathogenesis studies presents an additional limitation to translatability. An immunocompetent mouse is needed to fully understand immune-induced pathology and develop effective host-directed interventions. In addition, neonatal mice are neurodevelopmentally equivalent to a third trimester fetus [<xref rid="B69-viruses-17-00261" ref-type="bibr">69</xref>], which limits their translatability to both adult humans and children less than two years of age, one of the most vulnerable populations to neurological alphavirus infection.</p></sec></sec><sec id="sec3-viruses-17-00261"><title>3. The Role of Host-Pathogen Interactions on Alphavirus Pathogenesis</title><p><xref rid="viruses-17-00261-f001" ref-type="fig">Figure 1</xref> summarizes select aspects of the anti-alphaviral response discussed in this section.</p><sec id="sec3dot1-viruses-17-00261"><title>3.1. Viral Factors</title><p>Alphaviruses are made up of structural (sP) and non-structural (nsP) proteins critical for promoting virus replication while hindering antiviral cellular responses. sPs make up the virions and include the capsid protein and glycoproteins. The E1 and E2 glycoproteins facilitate attachment and entry into host cells and are the primary targets for neutralizing antibodies [<xref rid="B35-viruses-17-00261" ref-type="bibr">35</xref>]. As mentioned previously, a single point mutation in the E1 glycoprotein acquired by CHIKV (A226V) has allowed the virus to utilize <italic toggle="yes">Ae. albopictus</italic> in addition to <italic toggle="yes">Ae. aegypti</italic> as transmission vectors [<xref rid="B14-viruses-17-00261" ref-type="bibr">14</xref>]. The capsid protein is critical for forming viral particles that encapsulate the viral genome [<xref rid="B35-viruses-17-00261" ref-type="bibr">35</xref>]. nsPs contain the core enzymes that are necessary for viral replication but also combat host antiviral mechanisms [<xref rid="B35-viruses-17-00261" ref-type="bibr">35</xref>]. nsP1 and nsP2 disrupt immune signaling pathways, which inhibit antiviral gene expression [<xref rid="B35-viruses-17-00261" ref-type="bibr">35</xref>]. nsP3 is critical for viral replication and, as the least conserved nsP of the alphavirus proteome, has a high potential for acquiring mutations beneficial to the virus [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>,<xref rid="B35-viruses-17-00261" ref-type="bibr">35</xref>]. An extensive review of the viral factors mediating CHIKV virulence has been published by Freppel et al. [<xref rid="B35-viruses-17-00261" ref-type="bibr">35</xref>].</p><p>Data on how viral factors affect neuroinvasion during CHIKV, ONNV, MAYV, and RRV infection are limited. However, during SINV infection in mice, while multiple mechanisms are important for neuroinvasion, the E2 glycoprotein is the primary driver [<xref rid="B91-viruses-17-00261" ref-type="bibr">91</xref>,<xref rid="B92-viruses-17-00261" ref-type="bibr">92</xref>]. Furthermore, during SFV infection, E2 is important for crossing the blood-brain barrier (BBB) through interactions with glycosaminoglycans (GAGs) [<xref rid="B93-viruses-17-00261" ref-type="bibr">93</xref>]. Therefore, it is reasonable to assume that mutations in the sPs of other alphaviruses could enhance susceptibility to neuroinvasion, thus potentially leading to neurological disease.</p><p>Alphaviruses can counteract different antiviral cellular factors and immune mechanisms, thus increasing virulence [<xref rid="B94-viruses-17-00261" ref-type="bibr">94</xref>,<xref rid="B95-viruses-17-00261" ref-type="bibr">95</xref>]. Type I interferons (IFNs) are crucial for controlling initial viral infection, making the IFN pathway a common target for viruses [<xref rid="B95-viruses-17-00261" ref-type="bibr">95</xref>]. The cyclic GMP-AMP synthase (cGAS) stimulator of IFN genes (STING) pathway plays an integral part in the innate immune system by detecting double-stranded DNA (dsDNA), which leads to stimulation of IFN-stimulated genes (ISGs) and expression of type I IFNs [<xref rid="B95-viruses-17-00261" ref-type="bibr">95</xref>]. During the first few hours of CHIKV infection, cGAS expression is downregulated by viral capsid protein, and viral nsP1 interacts with STING to decrease type I IFN expression, resulting in higher viral loads and delayed clearance [<xref rid="B94-viruses-17-00261" ref-type="bibr">94</xref>,<xref rid="B95-viruses-17-00261" ref-type="bibr">95</xref>]. cGAS also plays a role in controlling ONNV, MAYV, and RRV infection [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>,<xref rid="B96-viruses-17-00261" ref-type="bibr">96</xref>], suggesting other alphaviruses may have developed similar innate immune evasion strategies.</p><p>With CHIKV, we can compare virus strains belonging to different phylogenetic lineages to understand further how viral genetic diversity affects neuroinvasion. Compared to an Asian CHIKV strain isolated in the 1960s, an ECSA-lineage CHIKV strain isolated from the 2006 La Reunion outbreak was found to induce increased foot swelling associated with infiltration of mononuclear cells and higher serum proinflammatory cytokine concentrations in mice [<xref rid="B97-viruses-17-00261" ref-type="bibr">97</xref>]; no virus was detected in mouse brains during the study. However, another study demonstrated that CHIKV-induced neurological disease in young adult B6 mice was strain dependent, with an ECSA-lineage CHIKV isolated during an outbreak in Sri Lanka showing increased disease severity compared to an Asian CHIKV isolated during an outbreak in the Caribbean island of San Martin [<xref rid="B70-viruses-17-00261" ref-type="bibr">70</xref>]. In contrast, when comparing two CHIKVs isolated in Malaysia, the Asian-lineage strain showed higher mortality and increased expression of apoptotic genes in suckling mice compared to the ECSA-lineage strain [<xref rid="B50-viruses-17-00261" ref-type="bibr">50</xref>]. Further work is needed to dissect what viral and host factors drive CHIKV strain-dependent disease severity, which will allow for better identification of vaccine targets and treatment strategies.</p></sec><sec id="sec3dot2-viruses-17-00261"><title>3.2. Host Factors</title><p>In addition to viral factors, multiple host factors, including age [<xref rid="B79-viruses-17-00261" ref-type="bibr">79</xref>], immune pathways [<xref rid="B83-viruses-17-00261" ref-type="bibr">83</xref>,<xref rid="B98-viruses-17-00261" ref-type="bibr">98</xref>,<xref rid="B99-viruses-17-00261" ref-type="bibr">99</xref>,<xref rid="B100-viruses-17-00261" ref-type="bibr">100</xref>], and host genetics [<xref rid="B90-viruses-17-00261" ref-type="bibr">90</xref>], have been found to affect alphavirus neuropathogenesis. In humans, the nature of neurological disease developed by patients infected with CHIKV tends to depend on the individual&#x02019;s age, with young children and elderly adults with comorbidities more likely to develop CNS disease and middle-aged adults tending to develop autoimmune-mediated peripheral neuropathies [<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>]. During a CHIKV outbreak in Honduras in 2015, of the children less than one year of age admitted to a hospital with a CHIKV diagnosis confirmed by PCR, 24% developed neurological disease, such as meningoencephalitis and seizures [<xref rid="B40-viruses-17-00261" ref-type="bibr">40</xref>]; in contrast, only 7% of adults admitted to the same hospital with a CHIKV diagnosis developed neurological complications [<xref rid="B41-viruses-17-00261" ref-type="bibr">41</xref>]. Similar enhanced age-related susceptibility to CHIKV-induced mortality has been observed in mice [<xref rid="B70-viruses-17-00261" ref-type="bibr">70</xref>]. ONNV and MAYV also show a correlation between age and mortality in mice. Only 50% of 6-week-old <italic toggle="yes">Stat1<sup>&#x02212;/&#x02212;</sup></italic> mice survive ONNV infection, compared to 100% of 12&#x02013;16-week-old mice [<xref rid="B55-viruses-17-00261" ref-type="bibr">55</xref>]. For MAYV, while 100% mortality has been observed in 6-day-old SV129 mice, 8-week-old mice show 100% survival [<xref rid="B74-viruses-17-00261" ref-type="bibr">74</xref>]. In addition, RRV-induced myositis shows similar age dependence in mice [<xref rid="B101-viruses-17-00261" ref-type="bibr">101</xref>]; however, this does not reflect clinical findings with RRV infection, where individuals under the age of 18 are primarily asymptomatic [<xref rid="B7-viruses-17-00261" ref-type="bibr">7</xref>,<xref rid="B33-viruses-17-00261" ref-type="bibr">33</xref>].</p><p>The human population is heterogeneous, and host genetics are known to affect susceptibility to viral infections, including alphaviruses [<xref rid="B102-viruses-17-00261" ref-type="bibr">102</xref>]. Genetic mutations in cell surface receptors can alter viral entry into target cells [<xref rid="B88-viruses-17-00261" ref-type="bibr">88</xref>], and markers associated with altered susceptibility to infection and disease outcome with CHIKV and other Old World alphaviruses include HLA, TLR-3, TLR-7, TLR-8, MXRA8, and CD209 (DC-SIGN) [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>,<xref rid="B9-viruses-17-00261" ref-type="bibr">9</xref>,<xref rid="B35-viruses-17-00261" ref-type="bibr">35</xref>,<xref rid="B88-viruses-17-00261" ref-type="bibr">88</xref>,<xref rid="B102-viruses-17-00261" ref-type="bibr">102</xref>]. While studies evaluating the role of genetics on alphavirus-induced neurological disease are limited, encephalomyelitis following RRV infection has been reported in neonatal BALB/c mice, but not adult B6 mice; the extent to which this altered susceptibility is driven by age versus mouse strain is unclear [<xref rid="B76-viruses-17-00261" ref-type="bibr">76</xref>,<xref rid="B103-viruses-17-00261" ref-type="bibr">103</xref>]. In contrast, disease susceptibility differences between these two mouse strains have been more definitively seen following SINV NSV and SFV infection [<xref rid="B84-viruses-17-00261" ref-type="bibr">84</xref>,<xref rid="B100-viruses-17-00261" ref-type="bibr">100</xref>,<xref rid="B104-viruses-17-00261" ref-type="bibr">104</xref>,<xref rid="B105-viruses-17-00261" ref-type="bibr">105</xref>]. BALB/c and B6 mice infected with the SFV mutant M9 showed differences in disease manifestations, with BALB/c mice showing more severe myelin vacuolation and demyelination, but B6 mice demonstrating higher mortality [<xref rid="B84-viruses-17-00261" ref-type="bibr">84</xref>]. Natural differences in the immune response between strains could explain this variation in clinical outcome; BALB/c mice tend to skew towards a Th2 immune response [<xref rid="B106-viruses-17-00261" ref-type="bibr">106</xref>], while B6 mice tend to skew towards a Th1 response [<xref rid="B107-viruses-17-00261" ref-type="bibr">107</xref>]. These studies highlight host genetics&#x02019; roles in disease outcomes during infection with alphaviruses. It is important to note that both neuroinvasion and neurovirulence are complex processes and involve the interplay of both host and viral factors. Future work should integrate host systems genetic approaches, such as those described above, with methods evaluating viral genetics to understand these complex host-pathogen interactions fully.</p><p>Co-infections in the host can also play a significant role in alphavirus-induced disease outcomes. Mechanisms include excessive immune activation and widespread inflammation that can spread to the CNS, damaging neurons and impeding their functionality [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>,<xref rid="B94-viruses-17-00261" ref-type="bibr">94</xref>]. In addition, co-infections can affect the permeability of the BBB, and interactions between different pathogens may increase alphavirus virulence [<xref rid="B94-viruses-17-00261" ref-type="bibr">94</xref>]. The public health impact of CHIKV is further complicated in that CHIKV and flaviviruses DENV and ZIKV tend to circulate in the same geographic regions, are all transmitted primarily by <italic toggle="yes">Ae. aegypti</italic>, and share similar symptoms, which can lead to misdiagnosis [<xref rid="B2-viruses-17-00261" ref-type="bibr">2</xref>,<xref rid="B5-viruses-17-00261" ref-type="bibr">5</xref>,<xref rid="B108-viruses-17-00261" ref-type="bibr">108</xref>,<xref rid="B109-viruses-17-00261" ref-type="bibr">109</xref>]. Therefore, it would benefit the field to investigate co-infections with other viruses endemic in the same area as these Old World alphaviruses to further understand their interactions and how they can affect neurological disease.</p></sec><sec id="sec3dot3-viruses-17-00261"><title>3.3. Immune Responses and Immunopathogenesis</title><p>Most of our understanding of the immune system&#x02019;s role in alphavirus neuropathogenesis comes from studies using SINV and SFV in mice. Both the innate and adaptive immune responses are known to be critical for alphavirus clearance in the CNS. The innate immune system detects CHIKV through pattern recognition receptors (PRRs), which drive the priming of the adaptive immune response and promote inflammatory responses [<xref rid="B35-viruses-17-00261" ref-type="bibr">35</xref>,<xref rid="B94-viruses-17-00261" ref-type="bibr">94</xref>]. Type I IFNs play a significant role in protecting against alphavirus infection, with mice deficient in type I IFN pathways showing increased viral titers and disease severity [<xref rid="B67-viruses-17-00261" ref-type="bibr">67</xref>,<xref rid="B110-viruses-17-00261" ref-type="bibr">110</xref>,<xref rid="B111-viruses-17-00261" ref-type="bibr">111</xref>]. Studies have shown virus in the brains of ONNV-infected <italic toggle="yes">Stat1<sup>&#x02212;/&#x02212;</sup></italic> and A129 mice [<xref rid="B55-viruses-17-00261" ref-type="bibr">55</xref>], suggesting that type I IFN signaling plays a role in protecting against ONNV neuroinvasion [<xref rid="B67-viruses-17-00261" ref-type="bibr">67</xref>,<xref rid="B73-viruses-17-00261" ref-type="bibr">73</xref>,<xref rid="B74-viruses-17-00261" ref-type="bibr">74</xref>]. The innate immune response is also crucial for restricting MAYV infection, as adult type I IFN receptor-deficient (<italic toggle="yes">Ifnar<sup>&#x02212;/&#x02212;</sup>)</italic> mice develop severe disease [<xref rid="B74-viruses-17-00261" ref-type="bibr">74</xref>]. Macrophages play a role in RRV pathology, and muscle damage is inhibited when macrophage-toxic agents are administered to RRV-infected mice [<xref rid="B112-viruses-17-00261" ref-type="bibr">112</xref>], consistent with in vitro studies in RRV-infected striated muscle cells [<xref rid="B113-viruses-17-00261" ref-type="bibr">113</xref>]. Furthermore, macrophages might provide a route for RRV to gain entry into the brain during infection, serving as a &#x0201c;Trojan horse&#x0201d; for neuroinvasion [<xref rid="B114-viruses-17-00261" ref-type="bibr">114</xref>].</p><p>Clearance of alphaviruses from the CNS has been most thoroughly elucidated in mouse models of SINV infection. Clearance of infectious virus is dependent on cooperation between 1) IFN gamma (IFN&#x003b3;) and 2) anti-SINV antibody [<xref rid="B99-viruses-17-00261" ref-type="bibr">99</xref>,<xref rid="B115-viruses-17-00261" ref-type="bibr">115</xref>]. IFN&#x003b3; increases chemokines that attract B cells to the brain and promotes the skewing of IgG subclasses, aiding in viral clearance [<xref rid="B115-viruses-17-00261" ref-type="bibr">115</xref>]. However, IFN&#x003b3; also promotes neuropathology; mice deficient in the IFN&#x003b3; receptor have delayed viral clearance but also show minimal pathological changes in the CNS compared to wild-type mice with intact IFN&#x003b3; signaling [<xref rid="B99-viruses-17-00261" ref-type="bibr">99</xref>]. These findings illustrate the &#x0201c;double-edged&#x0201d; sword phenomenon seen with the immune response to many viruses, including alphaviruses.</p><p>Mouse models using SINV have shown that the immune system plays a pathogenic role during infection, with T cells, especially CD4+ T cells, serving as the primary drivers of pathology in the CNS. Infiltration of immune cells into the CNS correlates with neurological disease and mortality [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>,<xref rid="B98-viruses-17-00261" ref-type="bibr">98</xref>,<xref rid="B99-viruses-17-00261" ref-type="bibr">99</xref>]. SCID mice, which lack mature T and B cells, show minimal pathology and 100% survival following SINV NSV infection [<xref rid="B81-viruses-17-00261" ref-type="bibr">81</xref>]. T and B cells have been shown to play a role in demyelination during SFV infection; SCID mice show robust viral replication but reduced or delayed pathology following SFV infection [<xref rid="B86-viruses-17-00261" ref-type="bibr">86</xref>]. CD8+ T cells, but not CD4+ T cells, have been found to drive CNS damage, as depletion of CD8+ T cells reduces inflammation and eliminates demyelination [<xref rid="B116-viruses-17-00261" ref-type="bibr">116</xref>]. CHIKV-induced joint disease is driven by CD4+ T cells [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>,<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>,<xref rid="B72-viruses-17-00261" ref-type="bibr">72</xref>], and neurological infection with a more neurovirulent CHIKV strain has been associated with more CD4+ T cells infiltrating the CNS compared to less neurovirulent CHIKV strains [<xref rid="B70-viruses-17-00261" ref-type="bibr">70</xref>], suggesting a similar pathogenic mechanism occurs during CHIKV-induced neurological disease. In contrast, while CD4+ and CD8+ T cells infiltrate into muscle tissues in RRV-infected mice, innate immune components, such as complement component 3 (C3), as opposed to the adaptive immune response, appear to be a major driver of RRV-induced disease [<xref rid="B76-viruses-17-00261" ref-type="bibr">76</xref>,<xref rid="B117-viruses-17-00261" ref-type="bibr">117</xref>].</p></sec></sec><sec id="sec4-viruses-17-00261"><title>4. Medical Countermeasures Against Alphavirus-Induced Disease</title><p><xref rid="viruses-17-00261-t002" ref-type="table">Table 2</xref> summarizes the currently approved and potential countermeasures to combat Old World alphavirus-induced disease.</p><sec id="sec4dot1-viruses-17-00261"><title>4.1. Preventative Strategies Against Old World Alphaviruses</title><p>As all alphaviruses are transmitted by mosquitoes, controlling vectors is one of the most important strategies for combatting alphavirus-induced disease. Different vector control approaches include insecticides, removing vector habitats near urban areas, surveillance, and education [<xref rid="B132-viruses-17-00261" ref-type="bibr">132</xref>]. In 2017, the World Health Assembly approved the Global Vector Control Response developed by the World Health Organization (WHO). This strategic plan tackles vector-borne diseases, including CHIKV, through effective, locally adapted, sustainable vector control [<xref rid="B132-viruses-17-00261" ref-type="bibr">132</xref>]. In 2022, the WHO launched the collaborative Global Arbovirus Initiative, which aims to improve the surveillance, prevention, and control of arboviruses and specifically focuses on countries with the heaviest burden and multiple circulating arboviruses [<xref rid="B133-viruses-17-00261" ref-type="bibr">133</xref>].</p><p>Another strategy for preventing alphavirus-induced disease, and arguably the most crucial approach for preventing neurological disease cases, is vaccines. In late 2023, the live attenuated CHIKV vaccine VLA1553 was approved by the Food and Drug Administration for persons 18 years and older [<xref rid="B134-viruses-17-00261" ref-type="bibr">134</xref>]; similar approval was granted in Canada and Europe in mid-2024 [<xref rid="B135-viruses-17-00261" ref-type="bibr">135</xref>,<xref rid="B136-viruses-17-00261" ref-type="bibr">136</xref>], and regulatory review is currently ongoing in the United Kingdom and Brazil. The CHIKV vaccine encodes the La Reunion strain of CHIKV lacking 61 amino acids in nsP3, which are essential for infection [<xref rid="B137-viruses-17-00261" ref-type="bibr">137</xref>]. In the phase III clinical trial, neutralizing antibody titers were induced to protective concentrations and persisted through day 180 [<xref rid="B118-viruses-17-00261" ref-type="bibr">118</xref>]. However, this vaccine is not approved for young children, who are one of the most vulnerable populations, especially to neurological disease manifestations [<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>]. Two clinical trials targeting children are currently in progress: one for adolescents aged 12 to 17 (NCT04650399) and one for young children aged 1 to 11 (NCT06106581). Furthermore, the CHIKV vaccine is not yet available in endemic countries, heavily underscoring the need for additional alphavirus treatment options for affected regions.</p><p>Due to their narrow geographic distribution, only limited data on vaccine development efforts for MAYV and ONNV are available. Several vaccines for MAYV are in preclinical development [<xref rid="B9-viruses-17-00261" ref-type="bibr">9</xref>], including a live attenuated vaccine [<xref rid="B138-viruses-17-00261" ref-type="bibr">138</xref>], adenoviral vector vaccines [<xref rid="B57-viruses-17-00261" ref-type="bibr">57</xref>,<xref rid="B139-viruses-17-00261" ref-type="bibr">139</xref>,<xref rid="B140-viruses-17-00261" ref-type="bibr">140</xref>], and, more recently, particle-like vaccines [<xref rid="B141-viruses-17-00261" ref-type="bibr">141</xref>]. At the publishing of this article, none are currently in the clinical trial phase. However, with the spread of vectors and detection of both viruses in <italic toggle="yes">Ae. aegypti</italic>, the close phylogenetic relationship of CHIKV and MAYV [<xref rid="B142-viruses-17-00261" ref-type="bibr">142</xref>] may allow for cross-protection against MAYV infection with the CHIKV vaccine [<xref rid="B57-viruses-17-00261" ref-type="bibr">57</xref>]. Cross-protection against MAYV has been reported in mouse models, although the mice used were deficient in type I IFN and thus immunocompromised [<xref rid="B57-viruses-17-00261" ref-type="bibr">57</xref>]. No studies investigating cross-protection of VLA1553 with other alphaviruses have yet been reported. Unlike MAYV, as of 2024, no vaccines are in development for ONNV. Like MAYV, since ONNV and CHIKV are also closely related [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>], the possibility of cross-reactivity with CHIKV vaccines has been raised [<xref rid="B143-viruses-17-00261" ref-type="bibr">143</xref>]; however, the feasibility of the CHIKV vaccine cross-reacting with other Old World alphaviruses remains a hypothesis and requires formal evaluation.</p><p>RRV has no approved vaccine, but phase I/II and phase III vaccine studies have been completed. A phase III clinical trial investigating the safety and immunogenicity of a Vero-derived whole-cell RRV vaccine found that 91% of participants 16 to 59 years old and 76% of participants aged 60 years or older achieved strong RRV-specific neutralizing antibody titers [<xref rid="B119-viruses-17-00261" ref-type="bibr">119</xref>]. However, the low incidence of RRV in Australia precluded the assessment of vaccine efficacy. As of December 2024, no other RRV vaccine approvals or trials are ongoing.</p></sec><sec id="sec4dot2-viruses-17-00261"><title>4.2. Treatments for Old World Alphavirus Infection</title><p>As of writing this review, while no post-exposure treatments have been approved for any Old World alphaviruses, several antiviral drugs are under investigation (<xref rid="viruses-17-00261-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B121-viruses-17-00261" ref-type="bibr">121</xref>,<xref rid="B122-viruses-17-00261" ref-type="bibr">122</xref>,<xref rid="B123-viruses-17-00261" ref-type="bibr">123</xref>]. For CHIKV, 3-methyltoxoflavin is a potent protein disulfide isomerase inhibitor that impedes E2-E1 folding and assembly in CHIKV but not in other alphaviruses [<xref rid="B120-viruses-17-00261" ref-type="bibr">120</xref>]. Chloroquine has been shown to inhibit multiple viruses in vitro, including SINV, SFV, CHIKV, and MAYV by targeting viral uncoating [<xref rid="B124-viruses-17-00261" ref-type="bibr">124</xref>,<xref rid="B125-viruses-17-00261" ref-type="bibr">125</xref>]. However, a clinical trial studying the effect of chloroquine against acute CHIKV infection did not provide significant benefit [<xref rid="B125-viruses-17-00261" ref-type="bibr">125</xref>].</p><p>Monoclonal antibodies (mAbs) for both prophylaxis and treatment against alphaviruses have been studied extensively and are especially promising due to their cross-neutralizing potential [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>]. Multiple anti-CHIKV mAbs targeting the E2 glycoproteins have been evaluated, with some conferring protection in mouse models [<xref rid="B20-viruses-17-00261" ref-type="bibr">20</xref>,<xref rid="B126-viruses-17-00261" ref-type="bibr">126</xref>,<xref rid="B127-viruses-17-00261" ref-type="bibr">127</xref>,<xref rid="B128-viruses-17-00261" ref-type="bibr">128</xref>]. Interestingly, two anti-CHIKV mAbs have been shown to protect against not only CHIKV infections but also against MAYV, ONNV, and RRV [<xref rid="B126-viruses-17-00261" ref-type="bibr">126</xref>,<xref rid="B129-viruses-17-00261" ref-type="bibr">129</xref>]. A lipid nanoparticle-encapsulated messenger RNA (mRNA-1944) developed by Moderna showed promise in a phase I clinical trial [<xref rid="B130-viruses-17-00261" ref-type="bibr">130</xref>]; however, current plans for phase II trials are unknown [<xref rid="B35-viruses-17-00261" ref-type="bibr">35</xref>].</p><p>Because no approved treatments for alphavirus-induced disease are available, treatment is limited to symptomatic care [<xref rid="B144-viruses-17-00261" ref-type="bibr">144</xref>]. For neurological complications following CHIKV infection, symptomatic care is based on the physicians&#x02019; assumption that the neuropathological process is virus or host-immune driven. When the assumed mechanism is virus driven, approaches that mitigate symptoms but do not directly combat the virus, such as non-steroidal anti-inflammatory drugs (NSAIDs) to relieve pain and reduce fever, are used [<xref rid="B3-viruses-17-00261" ref-type="bibr">3</xref>,<xref rid="B9-viruses-17-00261" ref-type="bibr">9</xref>,<xref rid="B20-viruses-17-00261" ref-type="bibr">20</xref>,<xref rid="B35-viruses-17-00261" ref-type="bibr">35</xref>]. However, immunosuppressives are used when the mechanism is assumed to be immune mediated, such as with processes like GBS [<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>].</p></sec><sec id="sec4dot3-viruses-17-00261"><title>4.3. Considerations for Treating Neurological Disease Caused by Old World Alphaviruses</title><p>The nature of neurological disease induced by Old World alphaviruses presents a significant challenge for developing potential treatments. Infection with Old World alphaviruses is usually not diagnosed until patients present with neurological complications; at this point, replicating virus, and often even viral RNA, are generally no longer detectable. Antivirals, mAbs, and drugs targeting virus entry and replication are, therefore, not likely to be effective solo treatment options once neurological symptoms are present. Antiviral treatments alone may be limited in alleviating neurological symptoms, as pathology is primarily immune driven [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>], and a combination of antivirals and host-directed interventions may be a more effective treatment approach. Antivirals can target viral replication, which may reduce viral load and modulate the immune response to mitigate CNS damage and neurological symptom development. In theory, treatments that target the immune response represent a promising approach for treating neurological complications. For example, treatment for GBS, an immune-mediated neurological condition occasionally induced by CHIKV infection, involves eliminating harmful antibodies through plasmapheresis or administering intravenous immunoglobulin from healthy patients that suppresses the immune system [<xref rid="B12-viruses-17-00261" ref-type="bibr">12</xref>]. However, developing effective treatments that can be targeted to alleviate and stop neurological damage requires an increased understanding of host-mediated mechanisms behind Old World alphavirus-induced neurological disease. Finally, once neurological symptoms are unmanageable enough for patients to seek medical help, the damage to the CNS is usually severe and difficult to reverse [<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>,<xref rid="B48-viruses-17-00261" ref-type="bibr">48</xref>,<xref rid="B53-viruses-17-00261" ref-type="bibr">53</xref>]. Therefore, while efforts to develop post-exposure treatments should continue to be pursued, preventives, such as vaccines, likely represent the most effective medical countermeasures to combat alphaviruses and should be made available to vulnerable populations in endemic countries.</p></sec></sec><sec sec-type="conclusions" id="sec5-viruses-17-00261"><title>5. Conclusions</title><p>As global temperatures rise and mosquito vectors spread to new geographical territories, alphaviruses are a progressive public health threat. Cases of neurological disease induced by CHIKV infection are increasingly being identified, and other Old World alphaviruses have the potential to cause similar atypical disease manifestations. Because neurological symptoms often do not appear until viremia is no longer detectable in the patient, supporting the development of effective preventative measures is especially critical. While the United States, Canada, and Europe have approved a live-attenuated CHIKV vaccine, it is not yet approved or available in endemic countries, highlighting the importance of making preventatives accessible to those most in need. Furthermore, as the immune response is strongly implicated as the primary driver of Old World alphavirus-induced neurological disease, therapies that target that aberrant immune response are likely to be more successful in mitigating damage to the CNS than virus-targeting approaches. However, while the immune response to alphaviruses can be pathogenic, it is also critical for protecting the patient by clearing the infection and preventing persistent viral RNA from reactivating. Therefore, it is of utmost importance to develop animal models of neurological disease induced by CHIKV, ONNV, MAYV, and RRV that better reflect the disease process seen in humans in conjunction with the already well-characterized mouse models of SINV and SFV to determine which pathogenic immune factors are best to target.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Original draft preparation, A.M.L.; review and editing, A.M.L. and V.K.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-00261"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>L.E.</given-names></name>
<name><surname>Martin</surname><given-names>S.W.</given-names></name>
<name><surname>Lindsey</surname><given-names>N.P.</given-names></name>
<name><surname>Lehman</surname><given-names>J.A.</given-names></name>
<name><surname>Rivera</surname><given-names>A.</given-names></name>
<name><surname>Kolsin</surname><given-names>J.</given-names></name>
<name><surname>Landry</surname><given-names>K.</given-names></name>
<name><surname>Staples</surname><given-names>J.E.</given-names></name>
<name><surname>Sharp</surname><given-names>T.M.</given-names></name>
<name><surname>Paz-Bailey</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Epidemiology of Dengue, Chikungunya, and Zika Virus Disease in U.S. States and Territories, 2017</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2019</year><volume>101</volume><fpage>884</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.19-0309</pub-id><pub-id pub-id-type="pmid">31436154</pub-id>
</element-citation></ref><ref id="B2-viruses-17-00261"><label>2.</label><element-citation publication-type="webpage"><article-title>Geographical Expansion of Cases of Dengue and Chikungunya beyond the Historical Areas of Transmission in the Region of the Americas</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON448" ext-link-type="uri">https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON448</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-20">(accessed on 20 November 2024)</date-in-citation></element-citation></ref><ref id="B3-viruses-17-00261"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ming</surname><given-names>S.T.J.</given-names></name>
<name><surname>Jun</surname><given-names>K.T.Y.</given-names></name>
<name><surname>Carissimo</surname><given-names>G.</given-names></name>
</person-group><article-title>Pathogenicity and Virulence of O&#x02019;nyong-Nyong Virus: A Less Studied Togaviridae with Pandemic Potential</article-title><source>Virulence</source><year>2024</year><volume>15</volume><fpage>2355201</fpage><pub-id pub-id-type="doi">10.1080/21505594.2024.2355201</pub-id><pub-id pub-id-type="pmid">38797948</pub-id>
</element-citation></ref><ref id="B4-viruses-17-00261"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Espinal</surname><given-names>M.A.</given-names></name>
<name><surname>Andrus</surname><given-names>J.K.</given-names></name>
<name><surname>Jauregui</surname><given-names>B.</given-names></name>
<name><surname>Waterman</surname><given-names>S.H.</given-names></name>
<name><surname>Morens</surname><given-names>D.M.</given-names></name>
<name><surname>Santos</surname><given-names>J.I.</given-names></name>
<name><surname>Horstick</surname><given-names>O.</given-names></name>
<name><surname>Francis</surname><given-names>L.A.</given-names></name>
<name><surname>Olson</surname><given-names>D.</given-names></name>
</person-group><article-title>Emerging and Reemerging <italic toggle="yes">Aedes</italic> -Transmitted Arbovirus Infections in the Region of the Americas: Implications for Health Policy</article-title><source>Am. J. Public Health</source><year>2019</year><volume>109</volume><fpage>387</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2018.304849</pub-id><pub-id pub-id-type="pmid">30676796</pub-id>
</element-citation></ref><ref id="B5-viruses-17-00261"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Natrajan</surname><given-names>M.S.</given-names></name>
<name><surname>Rojas</surname><given-names>A.</given-names></name>
<name><surname>Waggoner</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Beyond Fever and Pain: Diagnostic Methods for Chikungunya Virus</article-title><source>J. Clin. Microbiol.</source><year>2019</year><volume>57</volume><elocation-id>e00350</elocation-id><pub-id pub-id-type="doi">10.1128/JCM.00350-19</pub-id><pub-id pub-id-type="pmid">30995993</pub-id>
</element-citation></ref><ref id="B6-viruses-17-00261"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Paredes</surname><given-names>A.</given-names></name>
<name><surname>Weaver</surname><given-names>S.</given-names></name>
<name><surname>Watowich</surname><given-names>S.</given-names></name>
<name><surname>Chiu</surname><given-names>W.</given-names></name>
</person-group><article-title>Structural Biology of Old World and New World Alphaviruses</article-title><source>Infectious Diseases from Nature: Mechanisms of Viral Emergence and Persistence</source><person-group person-group-type="editor">
<name><surname>Peters</surname><given-names>C.J.</given-names></name>
<name><surname>Calisher</surname><given-names>C.H.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Vienna, Austria</publisher-loc><year>2005</year><fpage>179</fpage><lpage>185</lpage></element-citation></ref><ref id="B7-viruses-17-00261"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flies</surname><given-names>E.J.</given-names></name>
<name><surname>Lau</surname><given-names>C.L.</given-names></name>
<name><surname>Carver</surname><given-names>S.</given-names></name>
<name><surname>Weinstein</surname><given-names>P.</given-names></name>
</person-group><article-title>Another Emerging Mosquito-Borne Disease? Endemic Ross River Virus Transmission in the Absence of Marsupial Reservoirs</article-title><source>BioScience</source><year>2018</year><volume>68</volume><fpage>288</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1093/biosci/biy011</pub-id></element-citation></ref><ref id="B8-viruses-17-00261"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marinho</surname><given-names>M.D.S.</given-names></name>
<name><surname>Ferreira</surname><given-names>G.M.</given-names></name>
<name><surname>Grosche</surname><given-names>V.R.</given-names></name>
<name><surname>Nicolau-Junior</surname><given-names>N.</given-names></name>
<name><surname>Campos</surname><given-names>T.d.L.</given-names></name>
<name><surname>Santos</surname><given-names>I.A.</given-names></name>
<name><surname>Jardim</surname><given-names>A.C.G.</given-names></name>
</person-group><article-title>Evolutionary Profile of Mayaro Virus in the Americas: An Update into Genome Variability</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>809</elocation-id><pub-id pub-id-type="doi">10.3390/v16050809</pub-id><pub-id pub-id-type="pmid">38793690</pub-id>
</element-citation></ref><ref id="B9-viruses-17-00261"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>L.L.L.</given-names></name>
<name><surname>Tom</surname><given-names>R.</given-names></name>
<name><surname>Kim</surname><given-names>Y.C.</given-names></name>
</person-group><article-title>Mayaro Virus: An Emerging Alphavirus in the Americas</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>1297</elocation-id><pub-id pub-id-type="doi">10.3390/v16081297</pub-id><pub-id pub-id-type="pmid">39205271</pub-id>
</element-citation></ref><ref id="B10-viruses-17-00261"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suhrbier</surname><given-names>A.</given-names></name>
<name><surname>Jaffar-Bandjee</surname><given-names>M.-C.</given-names></name>
<name><surname>Gasque</surname><given-names>P.</given-names></name>
</person-group><article-title>Arthritogenic Alphaviruses&#x02014;An Overview</article-title><source>Nat. Rev. Rheumatol.</source><year>2012</year><volume>8</volume><fpage>420</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2012.64</pub-id><pub-id pub-id-type="pmid">22565316</pub-id>
</element-citation></ref><ref id="B11-viruses-17-00261"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Forrester</surname><given-names>N.L.</given-names></name>
<name><surname>Palacios</surname><given-names>G.</given-names></name>
<name><surname>Tesh</surname><given-names>R.B.</given-names></name>
<name><surname>Savji</surname><given-names>N.</given-names></name>
<name><surname>Guzman</surname><given-names>H.</given-names></name>
<name><surname>Sherman</surname><given-names>M.</given-names></name>
<name><surname>Weaver</surname><given-names>S.C.</given-names></name>
<name><surname>Lipkin</surname><given-names>W.I.</given-names></name>
</person-group><article-title>Genome-Scale Phylogeny of the Alphavirus Genus Suggests a Marine Origin</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>2729</fpage><lpage>2738</lpage><pub-id pub-id-type="doi">10.1128/JVI.05591-11</pub-id><pub-id pub-id-type="pmid">22190718</pub-id>
</element-citation></ref><ref id="B12-viruses-17-00261"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baxter</surname><given-names>V.K.</given-names></name>
<name><surname>Heise</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Immunopathogenesis of Alphaviruses</article-title><source>Adv. Virus Res.</source><year>2020</year><volume>107</volume><fpage>315</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/bs.aivir.2020.06.002</pub-id><pub-id pub-id-type="pmid">32711733</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00261"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Lima Cavalcanti</surname><given-names>T.Y.V.</given-names></name>
<name><surname>Pereira</surname><given-names>M.R.</given-names></name>
<name><surname>de Paula</surname><given-names>S.O.</given-names></name>
<name><surname>Franca</surname><given-names>R.F.D.O.</given-names></name>
</person-group><article-title>A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>969</elocation-id><pub-id pub-id-type="doi">10.3390/v14050969</pub-id><pub-id pub-id-type="pmid">35632709</pub-id>
</element-citation></ref><ref id="B14-viruses-17-00261"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bonn</surname><given-names>D.</given-names></name>
</person-group><article-title>How Did Chikungunya Reach the Indian Ocean?</article-title><source>Lancet Infect. Dis.</source><year>2006</year><volume>6</volume><fpage>543</fpage><pub-id pub-id-type="doi">10.1016/S1473-3099(06)70559-X</pub-id><pub-id pub-id-type="pmid">16953553</pub-id>
</element-citation></ref><ref id="B15-viruses-17-00261"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rezza</surname><given-names>G.</given-names></name>
<name><surname>Chen</surname><given-names>R.</given-names></name>
<name><surname>Weaver</surname><given-names>S.C.</given-names></name>
</person-group><article-title>O&#x02019;nyong-Nyong Fever: A Neglected Mosquito-Borne Viral Disease</article-title><source>Pathog. Glob. Health</source><year>2017</year><volume>111</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1080/20477724.2017.1355431</pub-id><pub-id pub-id-type="pmid">28829253</pub-id>
</element-citation></ref><ref id="B16-viruses-17-00261"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cottis</surname><given-names>S.</given-names></name>
<name><surname>Blisnick</surname><given-names>A.A.</given-names></name>
<name><surname>Failloux</surname><given-names>A.-B.</given-names></name>
<name><surname>Vernick</surname><given-names>K.D.</given-names></name>
</person-group><article-title>Determinants of Chikungunya and O&#x02019;nyong-Nyong Virus Specificity for Infection of Aedes and Anopheles Mosquito Vectors</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>589</elocation-id><pub-id pub-id-type="doi">10.3390/v15030589</pub-id><pub-id pub-id-type="pmid">36992298</pub-id>
</element-citation></ref><ref id="B17-viruses-17-00261"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>C.R.</given-names></name>
<name><surname>Downs</surname><given-names>W.G.</given-names></name>
<name><surname>Wattley</surname><given-names>G.H.</given-names></name>
<name><surname>Ahin</surname><given-names>N.W.</given-names></name>
<name><surname>Reese</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Mayaro Virus: A New Human Disease Agent</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1957</year><volume>6</volume><fpage>1012</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1957.6.1012</pub-id><pub-id pub-id-type="pmid">13487973</pub-id>
</element-citation></ref><ref id="B18-viruses-17-00261"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Acosta-Ampudia</surname><given-names>Y.</given-names></name>
<name><surname>Monsalve</surname><given-names>D.M.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>Y.</given-names></name>
<name><surname>Pacheco</surname><given-names>Y.</given-names></name>
<name><surname>Anaya</surname><given-names>J.-M.</given-names></name>
<name><surname>Ram&#x000ed;rez-Santana</surname><given-names>C.</given-names></name>
</person-group><article-title>Mayaro: An Emerging Viral Threat?</article-title><source>Emerg. Microbes Infect.</source><year>2018</year><volume>7</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41426-018-0163-5</pub-id><pub-id pub-id-type="pmid">29323102</pub-id>
</element-citation></ref><ref id="B19-viruses-17-00261"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Long</surname><given-names>K.C.</given-names></name>
<name><surname>Ziegler</surname><given-names>S.A.</given-names></name>
<name><surname>Thangamani</surname><given-names>S.</given-names></name>
<name><surname>Hausser</surname><given-names>N.L.</given-names></name>
<name><surname>Kochel</surname><given-names>T.J.</given-names></name>
<name><surname>Higgs</surname><given-names>S.</given-names></name>
<name><surname>Tesh</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Experimental Transmission of Mayaro Virus by Aedes Aegypti</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2011</year><volume>85</volume><fpage>750</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2011.11-0359</pub-id><pub-id pub-id-type="pmid">21976583</pub-id>
</element-citation></ref><ref id="B20-viruses-17-00261"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuen</surname><given-names>K.Y.</given-names></name>
<name><surname>Bielefeldt-Ohmann</surname><given-names>H.</given-names></name>
</person-group><article-title>Ross River Virus Infection: A Cross-Disciplinary Review with a Veterinary Perspective</article-title><source>Pathogens</source><year>2021</year><volume>10</volume><elocation-id>357</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10030357</pub-id><pub-id pub-id-type="pmid">33802851</pub-id>
</element-citation></ref><ref id="B21-viruses-17-00261"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>Kaur</surname><given-names>Y.</given-names></name>
<name><surname>Apostolopoulos</surname><given-names>V.</given-names></name>
<name><surname>Pant</surname><given-names>M.</given-names></name>
<name><surname>Gaidhane</surname><given-names>A.M.</given-names></name>
<name><surname>Zahiruddin</surname><given-names>Q.S.</given-names></name>
<name><surname>Singh</surname><given-names>M.P.</given-names></name>
<name><surname>Sah</surname><given-names>S.</given-names></name>
</person-group><article-title>The Rising Threat of Ross River Virus: Climate Change and Its Implications on Public Health in Australia</article-title><source>New Microbes New Infect.</source><year>2024</year><volume>60&#x02013;61</volume><fpage>101451</fpage><pub-id pub-id-type="doi">10.1016/j.nmni.2024.101451</pub-id></element-citation></ref><ref id="B22-viruses-17-00261"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doherty</surname><given-names>E.L.</given-names></name>
<name><surname>Carley</surname><given-names>J.G.</given-names></name>
<name><surname>Best</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Isolation of Ross River Virus from Man</article-title><source>Med. J. Aust.</source><year>1972</year><volume>1</volume><fpage>1083</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.1972.tb116646.x</pub-id><pub-id pub-id-type="pmid">5040017</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00261"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gyawali</surname><given-names>N.</given-names></name>
<name><surname>Taylor-Robinson</surname><given-names>A.W.</given-names></name>
<name><surname>Bradbury</surname><given-names>R.S.</given-names></name>
<name><surname>Potter</surname><given-names>A.</given-names></name>
<name><surname>Aaskov</surname><given-names>J.G.</given-names></name>
</person-group><article-title>Infection of Western Gray Kangaroos (<italic toggle="yes">Macropus fuliginosus</italic>) with Australian Arboviruses Associated with Human Infection</article-title><source>Vector-Borne Zoonotic Dis. Larchmt. N</source><year>2020</year><volume>20</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1089/vbz.2019.2467</pub-id><pub-id pub-id-type="pmid">31556842</pub-id>
</element-citation></ref><ref id="B24-viruses-17-00261"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Potter</surname><given-names>A.</given-names></name>
<name><surname>Johansen</surname><given-names>C.A.</given-names></name>
<name><surname>Fenwick</surname><given-names>S.</given-names></name>
<name><surname>Reid</surname><given-names>S.A.</given-names></name>
<name><surname>Lindsay</surname><given-names>M.D.A.</given-names></name>
</person-group><article-title>The Seroprevalence and Factors Associated with Ross River Virus Infection in Western Grey Kangaroos (<italic toggle="yes">Macropus fuliginosus</italic>) in Western Australia</article-title><source>Vector Borne Zoonotic Dis. Larchmt. N</source><year>2014</year><volume>14</volume><fpage>740</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1089/vbz.2014.1617</pub-id><pub-id pub-id-type="pmid">25325318</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00261"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doherty</surname><given-names>R.L.</given-names></name>
<name><surname>Standfast</surname><given-names>H.A.</given-names></name>
<name><surname>Domrow</surname><given-names>R.</given-names></name>
<name><surname>Wetters</surname><given-names>E.J.</given-names></name>
<name><surname>Whitehead</surname><given-names>R.H.</given-names></name>
<name><surname>Carley</surname><given-names>J.G.</given-names></name>
</person-group><article-title>Studies of the Epidemiology of Arthropod-Borne Virus Infections at Mitchell River Mission, Cape York Peninsula, North Queensland IV. Arbovirus Infections of Mosquitoes and Mammals, 1967&#x02013;1969</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1971</year><volume>65</volume><fpage>504</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(71)90161-1</pub-id><pub-id pub-id-type="pmid">4398589</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00261"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gylfe</surname><given-names>&#x000c5;.</given-names></name>
<name><surname>Ribers</surname><given-names>&#x000c5;.</given-names></name>
<name><surname>Forsman</surname><given-names>O.</given-names></name>
<name><surname>Bucht</surname><given-names>G.</given-names></name>
<name><surname>Alenius</surname><given-names>G.-M.</given-names></name>
<name><surname>W&#x000e5;llberg-Jonsson</surname><given-names>S.</given-names></name>
<name><surname>Ahlm</surname><given-names>C.</given-names></name>
<name><surname>Evander</surname><given-names>M.</given-names></name>
</person-group><article-title>Mosquitoborne Sindbis Virus Infection and Long-Term Illness</article-title><source>Emerg. Infect. Dis.</source><year>2018</year><volume>24</volume><fpage>1141</fpage><pub-id pub-id-type="doi">10.3201/eid2406.170892</pub-id><pub-id pub-id-type="pmid">29781426</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00261"><label>27.</label><element-citation publication-type="webpage"><article-title>Semliki Forest Virus: Cause of a Fatal Case of Human Encephalitis</article-title><comment>Available online: <ext-link xlink:href="https://www.science.org/doi/10.1126/science.424742" ext-link-type="uri">https://www.science.org/doi/10.1126/science.424742</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-05">(accessed on 5 December 2024)</date-in-citation></element-citation></ref><ref id="B28-viruses-17-00261"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mathiot</surname><given-names>C.C.</given-names></name>
<name><surname>Grimaud</surname><given-names>G.</given-names></name>
<name><surname>Garry</surname><given-names>P.</given-names></name>
<name><surname>Bouquety</surname><given-names>J.C.</given-names></name>
<name><surname>Mada</surname><given-names>A.</given-names></name>
<name><surname>Daguisy</surname><given-names>A.M.</given-names></name>
<name><surname>Georges</surname><given-names>A.J.</given-names></name>
</person-group><article-title>An Outbreak of Human Semliki Forest Virus Infections in Central African Republic</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1990</year><volume>42</volume><fpage>386</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1990.42.386</pub-id><pub-id pub-id-type="pmid">2158754</pub-id>
</element-citation></ref><ref id="B29-viruses-17-00261"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lim</surname><given-names>E.X.Y.</given-names></name>
<name><surname>Lee</surname><given-names>W.S.</given-names></name>
<name><surname>Madzokere</surname><given-names>E.T.</given-names></name>
<name><surname>Herrero</surname><given-names>L.J.</given-names></name>
</person-group><article-title>Mosquitoes as Suitable Vectors for Alphaviruses</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>84</elocation-id><pub-id pub-id-type="doi">10.3390/v10020084</pub-id><pub-id pub-id-type="pmid">29443908</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00261"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coffey</surname><given-names>L.L.</given-names></name>
<name><surname>Failloux</surname><given-names>A.-B.</given-names></name>
<name><surname>Weaver</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Chikungunya Virus&#x02013;Vector Interactions</article-title><source>Viruses</source><year>2014</year><volume>6</volume><fpage>4628</fpage><lpage>4663</lpage><pub-id pub-id-type="doi">10.3390/v6114628</pub-id><pub-id pub-id-type="pmid">25421891</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00261"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsetsarkin</surname><given-names>K.A.</given-names></name>
<name><surname>Vanlandingham</surname><given-names>D.L.</given-names></name>
<name><surname>McGee</surname><given-names>C.E.</given-names></name>
<name><surname>Higgs</surname><given-names>S.</given-names></name>
</person-group><article-title>A Single Mutation in Chikungunya Virus Affects Vector Specificity and Epidemic Potential</article-title><source>PLoS Pathog.</source><year>2007</year><volume>3</volume><elocation-id>e201</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0030201</pub-id><pub-id pub-id-type="pmid">18069894</pub-id>
</element-citation></ref><ref id="B32-viruses-17-00261"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lednicky</surname><given-names>J.</given-names></name>
<name><surname>De Rochars</surname><given-names>V.M.B.</given-names></name>
<name><surname>Elbadry</surname><given-names>M.</given-names></name>
<name><surname>Loeb</surname><given-names>J.</given-names></name>
<name><surname>Telisma</surname><given-names>T.</given-names></name>
<name><surname>Chavannes</surname><given-names>S.</given-names></name>
<name><surname>Anilis</surname><given-names>G.</given-names></name>
<name><surname>Cella</surname><given-names>E.</given-names></name>
<name><surname>Ciccozzi</surname><given-names>M.</given-names></name>
<name><surname>Okech</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Mayaro Virus in Child with Acute Febrile Illness, Haiti, 2015</article-title><source>Emerg. Infect. Dis.</source><year>2016</year><volume>22</volume><fpage>2000</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.3201/eid2211.161015</pub-id><pub-id pub-id-type="pmid">27767924</pub-id>
</element-citation></ref><ref id="B33-viruses-17-00261"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harley</surname><given-names>D.</given-names></name>
<name><surname>Sleigh</surname><given-names>A.</given-names></name>
<name><surname>Ritchie</surname><given-names>S.</given-names></name>
</person-group><article-title>Ross River Virus Transmission, Infection, and Disease: A Cross-Disciplinary Review</article-title><source>Clin. Microbiol. Rev.</source><year>2001</year><volume>14</volume><fpage>909</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1128/CMR.14.4.909-932.2001</pub-id><pub-id pub-id-type="pmid">11585790</pub-id>
</element-citation></ref><ref id="B34-viruses-17-00261"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopes Marques</surname><given-names>C.D.</given-names></name>
<name><surname>Ranzolin</surname><given-names>A.</given-names></name>
<name><surname>Cavalcanti</surname><given-names>N.G.</given-names></name>
<name><surname>Branco Pinto Duarte</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Arboviruses Related with Chronic Musculoskeletal Symptoms</article-title><source>Best Pract. Res. Clin. Rheumatol.</source><year>2020</year><volume>34</volume><fpage>101502</fpage><pub-id pub-id-type="doi">10.1016/j.berh.2020.101502</pub-id><pub-id pub-id-type="pmid">32312678</pub-id>
</element-citation></ref><ref id="B35-viruses-17-00261"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freppel</surname><given-names>W.</given-names></name>
<name><surname>Silva</surname><given-names>L.A.</given-names></name>
<name><surname>Stapleford</surname><given-names>K.A.</given-names></name>
<name><surname>Herrero</surname><given-names>L.J.</given-names></name>
</person-group><article-title>Pathogenicity and Virulence of Chikungunya Virus</article-title><source>Virulence</source><year>2024</year><volume>15</volume><fpage>2396484</fpage><pub-id pub-id-type="doi">10.1080/21505594.2024.2396484</pub-id><pub-id pub-id-type="pmid">39193780</pub-id>
</element-citation></ref><ref id="B36-viruses-17-00261"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wielanek</surname><given-names>A.C.</given-names></name>
<name><surname>Monredon</surname><given-names>J.D.</given-names></name>
<name><surname>Amrani</surname><given-names>M.E.</given-names></name>
<name><surname>Roger</surname><given-names>J.C.</given-names></name>
<name><surname>Serveaux</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Guillain-Barr&#x000e9; Syndrome Complicating a Chikungunya Virus Infection</article-title><source>Neurology</source><year>2007</year><volume>69</volume><fpage>2105</fpage><lpage>2107</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000277267.07220.88</pub-id><pub-id pub-id-type="pmid">18040016</pub-id>
</element-citation></ref><ref id="B37-viruses-17-00261"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lebrun</surname><given-names>G.</given-names></name>
<name><surname>Chadda</surname><given-names>K.</given-names></name>
<name><surname>Reboux</surname><given-names>A.-H.</given-names></name>
<name><surname>Martinet</surname><given-names>O.</given-names></name>
<name><surname>Ga&#x000fc;z&#x000e8;re</surname><given-names>B.-A.</given-names></name>
</person-group><article-title>Guillain-Barr&#x000e9; Syndrome after Chikungunya Infection</article-title><source>Emerg. Infect. Dis.</source><year>2009</year><volume>15</volume><fpage>495</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.3201/eid1503.071482</pub-id><pub-id pub-id-type="pmid">19239775</pub-id>
</element-citation></ref><ref id="B38-viruses-17-00261"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cerny</surname><given-names>T.</given-names></name>
<name><surname>Schwarz</surname><given-names>M.</given-names></name>
<name><surname>Schwarz</surname><given-names>U.</given-names></name>
<name><surname>Lemant</surname><given-names>J.</given-names></name>
<name><surname>G&#x000e9;rardin</surname><given-names>P.</given-names></name>
<name><surname>Keller</surname><given-names>E.</given-names></name>
</person-group><article-title>The Range of Neurological Complications in Chikungunya Fever</article-title><source>Neurocrit. Care</source><year>2017</year><volume>27</volume><fpage>447</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1007/s12028-017-0413-8</pub-id><pub-id pub-id-type="pmid">28741102</pub-id>
</element-citation></ref><ref id="B39-viruses-17-00261"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nelson</surname><given-names>J.</given-names></name>
<name><surname>Waggoner</surname><given-names>J.J.</given-names></name>
<name><surname>Sahoo</surname><given-names>M.K.</given-names></name>
<name><surname>Grant</surname><given-names>P.M.</given-names></name>
<name><surname>Pinsky</surname><given-names>B.A.</given-names></name>
</person-group><article-title>Encephalitis Caused by Chikungunya Virus in a Traveler from the Kingdom of Tonga</article-title><source>J. Clin. Microbiol.</source><year>2014</year><volume>52</volume><fpage>3459</fpage><lpage>3461</lpage><pub-id pub-id-type="doi">10.1128/JCM.01288-14</pub-id><pub-id pub-id-type="pmid">24958800</pub-id>
</element-citation></ref><ref id="B40-viruses-17-00261"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samra</surname><given-names>J.A.</given-names></name>
<name><surname>Hagood</surname><given-names>N.L.</given-names></name>
<name><surname>Summer</surname><given-names>A.</given-names></name>
<name><surname>Medina</surname><given-names>M.T.</given-names></name>
<name><surname>Holden</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Clinical Features and Neurologic Complications of Children Hospitalized with Chikungunya Virus in Honduras</article-title><source>J. Child Neurol.</source><year>2017</year><volume>32</volume><fpage>712</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1177/0883073817701879</pub-id><pub-id pub-id-type="pmid">28459170</pub-id>
</element-citation></ref><ref id="B41-viruses-17-00261"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ortiz-Quezada</surname><given-names>J.</given-names></name>
<name><surname>Rodriguez</surname><given-names>E.E.</given-names></name>
<name><surname>Hesse</surname><given-names>H.</given-names></name>
<name><surname>Molina</surname><given-names>L.</given-names></name>
<name><surname>Duran</surname><given-names>C.</given-names></name>
<name><surname>Lorenzana</surname><given-names>I.</given-names></name>
<name><surname>England</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Chikungunya Encephalitis, a Case Series from an Endemic Country</article-title><source>J. Neurol. Sci.</source><year>2021</year><volume>420</volume><fpage>117279</fpage><pub-id pub-id-type="doi">10.1016/j.jns.2020.117279</pub-id><pub-id pub-id-type="pmid">33373792</pub-id>
</element-citation></ref><ref id="B42-viruses-17-00261"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagpal</surname><given-names>K.</given-names></name>
<name><surname>Agarwal</surname><given-names>P.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Reddi</surname><given-names>R.</given-names></name>
</person-group><article-title>Chikungunya Infection Presenting as Mild Encephalitis with a Reversible Lesion in the Splenium: A Case Report</article-title><source>J. Neurovirol.</source><year>2017</year><volume>23</volume><fpage>501</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1007/s13365-017-0515-2</pub-id><pub-id pub-id-type="pmid">28105556</pub-id>
</element-citation></ref><ref id="B43-viruses-17-00261"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kook</surname><given-names>D.</given-names></name>
<name><surname>Joe</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Yoo</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Chikungunya Encephalitis Presenting as Rhombencephalitis</article-title><source>J. Clin. Neurol.</source><year>2024</year><volume>20</volume><fpage>106</fpage><pub-id pub-id-type="doi">10.3988/jcn.2023.0151</pub-id><pub-id pub-id-type="pmid">38179641</pub-id>
</element-citation></ref><ref id="B44-viruses-17-00261"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inban</surname><given-names>P.</given-names></name>
<name><surname>Chandrasekaran</surname><given-names>S.H.</given-names></name>
<name><surname>Yadav</surname><given-names>P.K.</given-names></name>
<name><surname>Vijayakumar</surname><given-names>R.</given-names></name>
<name><surname>Elavia</surname><given-names>Z.</given-names></name>
<name><surname>Singh</surname><given-names>M.</given-names></name>
</person-group><article-title>A Rare Case of Chikungunya Encephalitis and Its Management: A Case Report and Literature Review</article-title><source>Clin. Case Rep.</source><year>2024</year><volume>12</volume><fpage>e8656</fpage><pub-id pub-id-type="doi">10.1002/ccr3.8656</pub-id><pub-id pub-id-type="pmid">38476832</pub-id>
</element-citation></ref><ref id="B45-viruses-17-00261"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mutricy</surname><given-names>R.</given-names></name>
<name><surname>Matheus</surname><given-names>S.</given-names></name>
<name><surname>Mosnier</surname><given-names>&#x000c9;.</given-names></name>
<name><surname>Martinez-Lorenzi</surname><given-names>E.</given-names></name>
<name><surname>De Laval</surname><given-names>F.</given-names></name>
<name><surname>Nacher</surname><given-names>M.</given-names></name>
<name><surname>Niemetzky</surname><given-names>F.</given-names></name>
<name><surname>Naudion</surname><given-names>P.</given-names></name>
<name><surname>Djossou</surname><given-names>F.</given-names></name>
<name><surname>Rousset</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Mayaro Virus Infection in French Guiana, a Cross Sectional Study 2003&#x02013;2019</article-title><source>Infect. Genet. Evol.</source><year>2022</year><volume>99</volume><fpage>105243</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2022.105243</pub-id><pub-id pub-id-type="pmid">35151887</pub-id>
</element-citation></ref><ref id="B46-viruses-17-00261"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scrimgeour</surname><given-names>E.M.</given-names></name>
<name><surname>Aaskov</surname><given-names>J.G.</given-names></name>
<name><surname>Matz</surname><given-names>L.R.</given-names></name>
</person-group><article-title>Ross River Virus Arthritis in Papua New Guinea</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1987</year><volume>81</volume><fpage>833</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(87)90045-9</pub-id><pub-id pub-id-type="pmid">2835834</pub-id>
</element-citation></ref><ref id="B47-viruses-17-00261"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lucas</surname><given-names>R.E.</given-names></name>
<name><surname>Qiao</surname><given-names>M.</given-names></name>
</person-group><article-title>A Case of Encephalitis in Central Australia Due to Ross River Virus?</article-title><source>Aust. N. Z. J. Med.</source><year>1999</year><volume>29</volume><fpage>268</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1111/j.1445-5994.1999.tb00695.x</pub-id><pub-id pub-id-type="pmid">10342029</pub-id>
</element-citation></ref><ref id="B48-viruses-17-00261"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robin</surname><given-names>S.</given-names></name>
<name><surname>Ramful</surname><given-names>D.</given-names></name>
<name><surname>Le Seach&#x02019;</surname><given-names>F.</given-names></name>
<name><surname>Jaffar-Bandjee</surname><given-names>M.-C.</given-names></name>
<name><surname>Rigou</surname><given-names>G.</given-names></name>
<name><surname>Alessandri</surname><given-names>J.-L.</given-names></name>
</person-group><article-title>Neurologic Manifestations of Pediatric Chikungunya Infection</article-title><source>J. Child Neurol.</source><year>2008</year><volume>23</volume><fpage>1028</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1177/0883073808314151</pub-id><pub-id pub-id-type="pmid">18287573</pub-id>
</element-citation></ref><ref id="B49-viruses-17-00261"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>da Costa</surname><given-names>V.G.</given-names></name>
<name><surname>Saivish</surname><given-names>M.V.</given-names></name>
<name><surname>Sinhorini</surname><given-names>P.F.</given-names></name>
<name><surname>Nogueira</surname><given-names>M.L.</given-names></name>
<name><surname>Rahal</surname><given-names>P.</given-names></name>
</person-group><article-title>A <italic toggle="yes">Meta</italic>-Analysis of Chikungunya Virus in Neurological Disorders</article-title><source>Infect. Dis. Now</source><year>2024</year><volume>54</volume><fpage>104938</fpage><pub-id pub-id-type="doi">10.1016/j.idnow.2024.104938</pub-id><pub-id pub-id-type="pmid">38885813</pub-id>
</element-citation></ref><ref id="B50-viruses-17-00261"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei Chiam</surname><given-names>C.</given-names></name>
<name><surname>Fun Chan</surname><given-names>Y.</given-names></name>
<name><surname>Chai Ong</surname><given-names>K.</given-names></name>
<name><surname>Thong Wong</surname><given-names>K.</given-names></name>
<name><surname>Sam</surname><given-names>I.-C.</given-names></name>
</person-group><article-title>Neurovirulence Comparison of Chikungunya Virus Isolates of the Asian and East/Central/South African Genotypes from Malaysia</article-title><source>J. Gen. Virol.</source><year>2015</year><volume>96</volume><fpage>3243</fpage><lpage>3254</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.000263</pub-id><pub-id pub-id-type="pmid">26276497</pub-id>
</element-citation></ref><ref id="B51-viruses-17-00261"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Souza</surname><given-names>W.M.</given-names></name>
<name><surname>Fumagalli</surname><given-names>M.J.</given-names></name>
<name><surname>de Lima</surname><given-names>S.T.S.</given-names></name>
<name><surname>Parise</surname><given-names>P.L.</given-names></name>
<name><surname>Carvalho</surname><given-names>D.C.M.</given-names></name>
<name><surname>Hernandez</surname><given-names>C.</given-names></name>
<name><surname>de Jesus</surname><given-names>R.</given-names></name>
<name><surname>Delafiori</surname><given-names>J.</given-names></name>
<name><surname>Candido</surname><given-names>D.S.</given-names></name>
<name><surname>Carregari</surname><given-names>V.C.</given-names></name>
<etal/>
</person-group><article-title>Pathophysiology of Chikungunya Virus Infection Associated with Fatal Outcomes</article-title><source>Cell Host Microbe</source><year>2024</year><volume>32</volume><fpage>606</fpage><lpage>622.e8</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2024.02.011</pub-id><pub-id pub-id-type="pmid">38479396</pub-id>
</element-citation></ref><ref id="B52-viruses-17-00261"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ganesan</surname><given-names>K.</given-names></name>
<name><surname>Diwan</surname><given-names>A.</given-names></name>
<name><surname>Shankar</surname><given-names>S.K.</given-names></name>
<name><surname>Desai</surname><given-names>S.B.</given-names></name>
<name><surname>Sainani</surname><given-names>G.S.</given-names></name>
<name><surname>Katrak</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Chikungunya Encephalomyeloradiculitis: Report of 2 Cases with Neuroimaging and 1 Case with Autopsy Findings</article-title><source>AJNR Am. J. Neuroradiol.</source><year>2008</year><volume>29</volume><fpage>1636</fpage><lpage>1637</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A1133</pub-id><pub-id pub-id-type="pmid">18566010</pub-id>
</element-citation></ref><ref id="B53-viruses-17-00261"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000e9;rardin</surname><given-names>P.</given-names></name>
<name><surname>Couderc</surname><given-names>T.</given-names></name>
<name><surname>Bintner</surname><given-names>M.</given-names></name>
<name><surname>Tournebize</surname><given-names>P.</given-names></name>
<name><surname>Renouil</surname><given-names>M.</given-names></name>
<name><surname>L&#x000e9;mant</surname><given-names>J.</given-names></name>
<name><surname>Boisson</surname><given-names>V.</given-names></name>
<name><surname>Borgherini</surname><given-names>G.</given-names></name>
<name><surname>Staikowsky</surname><given-names>F.</given-names></name>
<name><surname>Schramm</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Chikungunya Virus-Associated Encephalitis: A Cohort Study on La R&#x000e9;union Island, 2005&#x02013;2009</article-title><source>Neurology</source><year>2015</year><volume>86</volume><fpage>94</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002234</pub-id><pub-id pub-id-type="pmid">26609145</pub-id>
</element-citation></ref><ref id="B54-viruses-17-00261"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kiwanuka</surname><given-names>N.</given-names></name>
<name><surname>Sanders</surname><given-names>E.J.</given-names></name>
<name><surname>Rwaguma</surname><given-names>E.B.</given-names></name>
<name><surname>Kawamata</surname><given-names>J.</given-names></name>
<name><surname>Ssengooba</surname><given-names>F.P.</given-names></name>
<name><surname>Najjemba</surname><given-names>R.</given-names></name>
<name><surname>Were</surname><given-names>W.A.</given-names></name>
<name><surname>Lamunu</surname><given-names>M.</given-names></name>
<name><surname>Bagambisa</surname><given-names>G.</given-names></name>
<name><surname>Burkot</surname><given-names>T.R.</given-names></name>
<etal/>
</person-group><article-title>O&#x02019;Nyong-Nyong Fever in South-Central Uganda, 1996&#x02013;1997: Clinical Features and Validation of a Clinical Case Definition for Surveillance Purposes</article-title><source>Clin. Infect. Dis.</source><year>1999</year><volume>29</volume><fpage>1243</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1086/313462</pub-id><pub-id pub-id-type="pmid">10524970</pub-id>
</element-citation></ref><ref id="B55-viruses-17-00261"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seymour</surname><given-names>R.L.</given-names></name>
<name><surname>Rossi</surname><given-names>S.L.</given-names></name>
<name><surname>Bergren</surname><given-names>N.A.</given-names></name>
<name><surname>Plante</surname><given-names>K.S.</given-names></name>
<name><surname>Weaver</surname><given-names>S.C.</given-names></name>
</person-group><article-title>The Role of Innate versus Adaptive Immune Responses in a Mouse Model of O&#x02019;Nyong-Nyong Virus Infection</article-title><source>Am. Soc. Trop. Med. Hyg.</source><year>2013</year><volume>88</volume><fpage>1170</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.12-0674</pub-id><pub-id pub-id-type="pmid">23568285</pub-id>
</element-citation></ref><ref id="B56-viruses-17-00261"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bengue</surname><given-names>M.</given-names></name>
<name><surname>Ferraris</surname><given-names>P.</given-names></name>
<name><surname>Barthelemy</surname><given-names>J.</given-names></name>
<name><surname>Diagne</surname><given-names>C.T.</given-names></name>
<name><surname>Hamel</surname><given-names>R.</given-names></name>
<name><surname>Li&#x000e9;geois</surname><given-names>F.</given-names></name>
<name><surname>Nougair&#x000e8;de</surname><given-names>A.</given-names></name>
<name><surname>De Lamballerie</surname><given-names>X.</given-names></name>
<name><surname>Simonin</surname><given-names>Y.</given-names></name>
<name><surname>Pompon</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Mayaro Virus Infects Human Brain Cells and Induces a Potent Antiviral Response in Human Astrocytes</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>465</elocation-id><pub-id pub-id-type="doi">10.3390/v13030465</pub-id><pub-id pub-id-type="pmid">33799906</pub-id>
</element-citation></ref><ref id="B57-viruses-17-00261"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campos</surname><given-names>R.K.</given-names></name>
<name><surname>Preciado-Llanes</surname><given-names>L.</given-names></name>
<name><surname>Azar</surname><given-names>S.R.</given-names></name>
<name><surname>Kim</surname><given-names>Y.C.</given-names></name>
<name><surname>Brandon</surname><given-names>O.</given-names></name>
<name><surname>L&#x000f3;pez-Camacho</surname><given-names>C.</given-names></name>
<name><surname>Reyes-Sandoval</surname><given-names>A.</given-names></name>
<name><surname>Rossi</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection from Lethal Challenge in A129 Mouse Model</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>591885</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.591885</pub-id><pub-id pub-id-type="pmid">33224148</pub-id>
</element-citation></ref><ref id="B58-viruses-17-00261"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciota</surname><given-names>A.T.</given-names></name>
<name><surname>Kramer</surname><given-names>L.D.</given-names></name>
</person-group><article-title>Insights into Arbovirus Evolution and Adaptation from Experimental Studies</article-title><source>Viruses</source><year>2010</year><volume>2</volume><fpage>2594</fpage><lpage>2617</lpage><pub-id pub-id-type="doi">10.3390/v2122594</pub-id><pub-id pub-id-type="pmid">21994633</pub-id>
</element-citation></ref><ref id="B59-viruses-17-00261"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Condon</surname><given-names>R.J.</given-names></name>
<name><surname>Rouse</surname><given-names>I.L.</given-names></name>
</person-group><article-title>Acute Symptoms and Sequelae of Ross River Virus Infection in South-Western Australia: A Follow-up Study</article-title><source>Clin. Diagn. Virol.</source><year>1995</year><volume>3</volume><fpage>273</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/S0928-0197(94)00043-3</pub-id><pub-id pub-id-type="pmid">15566808</pub-id>
</element-citation></ref><ref id="B60-viruses-17-00261"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palha</surname><given-names>N.</given-names></name>
<name><surname>Guivel-Benhassine</surname><given-names>F.</given-names></name>
<name><surname>Briolat</surname><given-names>V.</given-names></name>
<name><surname>Lutfalla</surname><given-names>G.</given-names></name>
<name><surname>Sourisseau</surname><given-names>M.</given-names></name>
<name><surname>Ellett</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>C.-H.</given-names></name>
<name><surname>Lieschke</surname><given-names>G.J.</given-names></name>
<name><surname>Herbomel</surname><given-names>P.</given-names></name>
<name><surname>Schwartz</surname><given-names>O.</given-names></name>
<etal/>
</person-group><article-title>Real-Time Whole-Body Visualization of Chikungunya Virus Infection and Host Interferon Response in Zebrafish</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003619</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003619</pub-id><pub-id pub-id-type="pmid">24039582</pub-id>
</element-citation></ref><ref id="B61-viruses-17-00261"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Passoni</surname><given-names>G.</given-names></name>
<name><surname>Langevin</surname><given-names>C.</given-names></name>
<name><surname>Palha</surname><given-names>N.</given-names></name>
<name><surname>Mounce</surname><given-names>B.C.</given-names></name>
<name><surname>Briolat</surname><given-names>V.</given-names></name>
<name><surname>Affaticati</surname><given-names>P.</given-names></name>
<name><surname>De Job</surname><given-names>E.</given-names></name>
<name><surname>Joly</surname><given-names>J.-S.</given-names></name>
<name><surname>Vignuzzi</surname><given-names>M.</given-names></name>
<name><surname>Saleh</surname><given-names>M.-C.</given-names></name>
<etal/>
</person-group><article-title>Imaging of Viral Neuroinvasion in the Zebrafish Reveals That Sindbis and Chikungunya Viruses Favour Different Entry Routes</article-title><source>Dis. Model. Mech.</source><year>2017</year><volume>10</volume><fpage>847</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1242/dmm.029231</pub-id><pub-id pub-id-type="pmid">28483796</pub-id>
</element-citation></ref><ref id="B62-viruses-17-00261"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Labadie</surname><given-names>K.</given-names></name>
<name><surname>Larcher</surname><given-names>T.</given-names></name>
<name><surname>Joubert</surname><given-names>C.</given-names></name>
<name><surname>Mannioui</surname><given-names>A.</given-names></name>
<name><surname>Delache</surname><given-names>B.</given-names></name>
<name><surname>Brochard</surname><given-names>P.</given-names></name>
<name><surname>Guigand</surname><given-names>L.</given-names></name>
<name><surname>Dubreil</surname><given-names>L.</given-names></name>
<name><surname>Lebon</surname><given-names>P.</given-names></name>
<name><surname>Verrier</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Chikungunya Disease in Nonhuman Primates Involves Long-Term Viral Persistence in Macrophages</article-title><source>J. Clin. Investig.</source><year>2010</year><volume>120</volume><fpage>894</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1172/JCI40104</pub-id><pub-id pub-id-type="pmid">20179353</pub-id>
</element-citation></ref><ref id="B63-viruses-17-00261"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inglis</surname><given-names>F.M.</given-names></name>
<name><surname>Lee</surname><given-names>K.M.</given-names></name>
<name><surname>Chiu</surname><given-names>K.B.</given-names></name>
<name><surname>Purcell</surname><given-names>O.M.</given-names></name>
<name><surname>Didier</surname><given-names>P.J.</given-names></name>
<name><surname>Russell-Lodrigue</surname><given-names>K.</given-names></name>
<name><surname>Weaver</surname><given-names>S.C.</given-names></name>
<name><surname>Roy</surname><given-names>C.J.</given-names></name>
<name><surname>MacLean</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Neuropathogenesis of Chikungunya Infection: Astrogliosis and Innate Immune Activation</article-title><source>J. Neurovirol.</source><year>2016</year><volume>22</volume><fpage>140</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1007/s13365-015-0378-3</pub-id><pub-id pub-id-type="pmid">26419894</pub-id>
</element-citation></ref><ref id="B64-viruses-17-00261"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suckling</surname><given-names>A.J.</given-names></name>
<name><surname>Jagelman</surname><given-names>S.</given-names></name>
<name><surname>Webb</surname><given-names>H.E.</given-names></name>
</person-group><article-title>A Comparison of Brain Lysosomal Enzyme Activities in Four Experimental Togavirus Encephalitides</article-title><source>J. Neurol. Sci.</source><year>1978</year><volume>35</volume><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/0022-510X(78)90015-1</pub-id><pub-id pub-id-type="pmid">204753</pub-id>
</element-citation></ref><ref id="B65-viruses-17-00261"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teo</surname><given-names>T.-H.</given-names></name>
<name><surname>Lum</surname><given-names>F.-M.</given-names></name>
<name><surname>Claser</surname><given-names>C.</given-names></name>
<name><surname>Lulla</surname><given-names>V.</given-names></name>
<name><surname>Lulla</surname><given-names>A.</given-names></name>
<name><surname>Merits</surname><given-names>A.</given-names></name>
<name><surname>R&#x000e9;nia</surname><given-names>L.</given-names></name>
<name><surname>Ng</surname><given-names>L.F.P.</given-names></name>
</person-group><article-title>A Pathogenic Role for CD4+ T Cells during Chikungunya Virus Infection in Mice</article-title><source>J. Immunol.</source><year>2013</year><volume>190</volume><fpage>259</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202177</pub-id><pub-id pub-id-type="pmid">23209328</pub-id>
</element-citation></ref><ref id="B66-viruses-17-00261"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Priya</surname><given-names>R.</given-names></name>
<name><surname>Patro</surname><given-names>I.K.</given-names></name>
<name><surname>Parida</surname><given-names>M.M.</given-names></name>
</person-group><article-title>TLR3 Mediated Innate Immune Response in Mice Brain Following Infection with Chikungunya Virus</article-title><source>Virus Res.</source><year>2014</year><volume>189</volume><fpage>194</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2014.05.010</pub-id><pub-id pub-id-type="pmid">24905288</pub-id>
</element-citation></ref><ref id="B67-viruses-17-00261"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Couderc</surname><given-names>T.</given-names></name>
<name><surname>Chr&#x000e9;tien</surname><given-names>F.</given-names></name>
<name><surname>Schilte</surname><given-names>C.</given-names></name>
<name><surname>Disson</surname><given-names>O.</given-names></name>
<name><surname>Brigitte</surname><given-names>M.</given-names></name>
<name><surname>Guivel-Benhassine</surname><given-names>F.</given-names></name>
<name><surname>Touret</surname><given-names>Y.</given-names></name>
<name><surname>Barau</surname><given-names>G.</given-names></name>
<name><surname>Cayet</surname><given-names>N.</given-names></name>
<name><surname>Schuffenecker</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>A Mouse Model for Chikungunya: Young Age and Inefficient Type-I Interferon Signaling Are Risk Factors for Severe Disease</article-title><source>PLoS Pathog.</source><year>2008</year><volume>4</volume><elocation-id>e29</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0040029</pub-id><pub-id pub-id-type="pmid">18282093</pub-id>
</element-citation></ref><ref id="B68-viruses-17-00261"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Das</surname><given-names>T.</given-names></name>
<name><surname>Hoarau</surname><given-names>J.J.</given-names></name>
<name><surname>Bandjee</surname><given-names>M.C.J.</given-names></name>
<name><surname>Maquart</surname><given-names>M.</given-names></name>
<name><surname>Gasque</surname><given-names>P.</given-names></name>
</person-group><article-title>Multifaceted Innate Immune Responses Engaged by Astrocytes, Microglia and Resident Dendritic Cells Against Chikungunya Neuroinfection</article-title><source>J. Gen. Virol.</source><year>2015</year><volume>96</volume><fpage>294</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1099/vir.0.071175-0</pub-id><pub-id pub-id-type="pmid">25351727</pub-id>
</element-citation></ref><ref id="B69-viruses-17-00261"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Workman</surname><given-names>A.D.</given-names></name>
<name><surname>Charvet</surname><given-names>C.J.</given-names></name>
<name><surname>Clancy</surname><given-names>B.</given-names></name>
<name><surname>Darlington</surname><given-names>R.B.</given-names></name>
<name><surname>Finlay</surname><given-names>B.L.</given-names></name>
</person-group><article-title>Modeling Transformations of Neurodevelopmental Sequences across Mammalian Species</article-title><source>J. Neurosci.</source><year>2013</year><volume>33</volume><fpage>7368</fpage><lpage>7383</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5746-12.2013</pub-id><pub-id pub-id-type="pmid">23616543</pub-id>
</element-citation></ref><ref id="B70-viruses-17-00261"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>E.J.</given-names></name>
<name><surname>Knight</surname><given-names>A.C.</given-names></name>
<name><surname>Heise</surname><given-names>M.T.</given-names></name>
<name><surname>Baxter</surname><given-names>V.K.</given-names></name>
</person-group><article-title>Effect of Viral Strain and Host Age on Clinical Disease and Viral Replication in Immunocompetent Mouse Models of Chikungunya Encephalomyelitis</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1057</elocation-id><pub-id pub-id-type="doi">10.3390/v15051057</pub-id><pub-id pub-id-type="pmid">37243143</pub-id>
</element-citation></ref><ref id="B71-viruses-17-00261"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jain</surname><given-names>J.</given-names></name>
<name><surname>Narayanan</surname><given-names>V.</given-names></name>
<name><surname>Chaturvedi</surname><given-names>S.</given-names></name>
<name><surname>Pai</surname><given-names>S.</given-names></name>
<name><surname>Sunil</surname><given-names>S.</given-names></name>
</person-group><article-title>In Vivo Evaluation of Withania Somnifera-Based Indian Traditional Formulation (<italic toggle="yes">Amukkara choornam</italic>), Against Chikungunya Virus-Induced Morbidity and Arthralgia</article-title><source>J. Evid.-Based Integr. Med.</source><year>2018</year><volume>23</volume><fpage>2156587218757661</fpage><pub-id pub-id-type="doi">10.1177/2156587218757661</pub-id><pub-id pub-id-type="pmid">29484895</pub-id>
</element-citation></ref><ref id="B72-viruses-17-00261"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jain</surname><given-names>J.</given-names></name>
<name><surname>Narayanan</surname><given-names>V.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Shrinet</surname><given-names>J.</given-names></name>
<name><surname>Srivastava</surname><given-names>P.</given-names></name>
<name><surname>Chaturvedi</surname><given-names>S.</given-names></name>
<name><surname>Sunil</surname><given-names>S.</given-names></name>
</person-group><article-title>Establishment and Comparison of Pathogenicity and Related Neurotropism in Two Age Groups of Immune Competent Mice, C57BL/6J Using an Indian Isolate of Chikungunya Virus (CHIKV)</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>578</elocation-id><pub-id pub-id-type="doi">10.3390/v11060578</pub-id><pub-id pub-id-type="pmid">31242674</pub-id>
</element-citation></ref><ref id="B73-viruses-17-00261"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>F.M.</given-names></name>
<name><surname>Dias</surname><given-names>R.S.</given-names></name>
<name><surname>De Oliveira</surname><given-names>M.D.</given-names></name>
<name><surname>Costa</surname><given-names>I.C.T.A.</given-names></name>
<name><surname>Fernandes</surname><given-names>L.D.S.</given-names></name>
<name><surname>Pessoa</surname><given-names>C.R.</given-names></name>
<name><surname>Da Matta</surname><given-names>S.L.P.</given-names></name>
<name><surname>Costa</surname><given-names>V.V.</given-names></name>
<name><surname>Souza</surname><given-names>D.G.</given-names></name>
<name><surname>Da Silva</surname><given-names>C.C.</given-names></name>
<etal/>
</person-group><article-title>Animal Model of Arthritis and Myositis Induced by the Mayaro Virus</article-title><source>PLoS Negl. Trop. Dis.</source><year>2019</year><volume>13</volume><elocation-id>e0007375</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0007375</pub-id><pub-id pub-id-type="pmid">31050676</pub-id>
</element-citation></ref><ref id="B74-viruses-17-00261"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Figueiredo</surname><given-names>C.M.</given-names></name>
<name><surname>Neris</surname><given-names>R.L.d.S.</given-names></name>
<name><surname>Gavino-Leopoldino</surname><given-names>D.</given-names></name>
<name><surname>da Silva</surname><given-names>M.O.L.</given-names></name>
<name><surname>Almeida</surname><given-names>J.S.</given-names></name>
<name><surname>dos-Santos</surname><given-names>J.S.</given-names></name>
<name><surname>Figueiredo</surname><given-names>C.P.</given-names></name>
<name><surname>Bellio</surname><given-names>M.</given-names></name>
<name><surname>Bozza</surname><given-names>M.T.</given-names></name>
<name><surname>Assun&#x000e7;&#x000e3;o-Miranda</surname><given-names>I.</given-names></name>
</person-group><article-title>Mayaro Virus Replication Restriction and Induction of Muscular Inflammation in Mice Are Dependent on Age, Type-I Interferon Response, and Adaptive Immunity</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><elocation-id>2246</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.02246</pub-id><pub-id pub-id-type="pmid">31632368</pub-id>
</element-citation></ref><ref id="B75-viruses-17-00261"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>Y.-H.</given-names></name>
<name><surname>Teo</surname><given-names>T.-H.</given-names></name>
<name><surname>Torres-Ruesta</surname><given-names>A.</given-names></name>
<name><surname>Hartimath</surname><given-names>S.V.</given-names></name>
<name><surname>Chee</surname><given-names>R.S.-L.</given-names></name>
<name><surname>Khanapur</surname><given-names>S.</given-names></name>
<name><surname>Yong</surname><given-names>F.F.</given-names></name>
<name><surname>Ramasamy</surname><given-names>B.</given-names></name>
<name><surname>Cheng</surname><given-names>P.</given-names></name>
<name><surname>Rajarethinam</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Longitudinal [18F]FB-IL-2 PET Imaging to Assess the Immunopathogenicity of O&#x02019;nyong-Nyong Virus Infection</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>894</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.00894</pub-id><pub-id pub-id-type="pmid">32477364</pub-id>
</element-citation></ref><ref id="B76-viruses-17-00261"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morrison</surname><given-names>T.E.</given-names></name>
<name><surname>Whitmore</surname><given-names>A.C.</given-names></name>
<name><surname>Shabman</surname><given-names>R.S.</given-names></name>
<name><surname>Lidbury</surname><given-names>B.A.</given-names></name>
<name><surname>Mahalingam</surname><given-names>S.</given-names></name>
<name><surname>Heise</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Characterization of Ross River Virus Tropism and Virus-Induced Inflammation in a Mouse Model of Viral Arthritis and Myositis</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>737</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1128/JVI.80.2.737-749.2006</pub-id><pub-id pub-id-type="pmid">16378976</pub-id>
</element-citation></ref><ref id="B77-viruses-17-00261"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lidbury</surname><given-names>B.A.</given-names></name>
<name><surname>Rulli</surname><given-names>N.E.</given-names></name>
<name><surname>Musso</surname><given-names>C.M.</given-names></name>
<name><surname>Cossetto</surname><given-names>S.B.</given-names></name>
<name><surname>Zaid</surname><given-names>A.</given-names></name>
<name><surname>Suhrbier</surname><given-names>A.</given-names></name>
<name><surname>Rothenfluh</surname><given-names>H.S.</given-names></name>
<name><surname>Rolph</surname><given-names>M.S.</given-names></name>
<name><surname>Mahalingam</surname><given-names>S.</given-names></name>
</person-group><article-title>Identification and Characterization of a Ross River Virus Variant That Grows Persistently in Macrophages, Shows Altered Disease Kinetics in a Mouse Model, and Exhibits Resistance to Type I Interferon</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>5651</fpage><lpage>5663</lpage><pub-id pub-id-type="doi">10.1128/JVI.01189-10</pub-id><pub-id pub-id-type="pmid">21430046</pub-id>
</element-citation></ref><ref id="B78-viruses-17-00261"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weber</surname><given-names>W.C.</given-names></name>
<name><surname>Labriola</surname><given-names>C.S.</given-names></name>
<name><surname>Kreklywich</surname><given-names>C.N.</given-names></name>
<name><surname>Ray</surname><given-names>K.</given-names></name>
<name><surname>Haese</surname><given-names>N.N.</given-names></name>
<name><surname>Andoh</surname><given-names>T.F.</given-names></name>
<name><surname>Denton</surname><given-names>M.</given-names></name>
<name><surname>Medica</surname><given-names>S.</given-names></name>
<name><surname>Streblow</surname><given-names>M.M.</given-names></name>
<name><surname>Smith</surname><given-names>P.P.</given-names></name>
<etal/>
</person-group><article-title>Mayaro Virus Pathogenesis and Immunity in Rhesus Macaques</article-title><source>PLoS Negl. Trop. Dis.</source><year>2023</year><volume>17</volume><elocation-id>e0011742</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0011742</pub-id><pub-id pub-id-type="pmid">37983245</pub-id>
</element-citation></ref><ref id="B79-viruses-17-00261"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Role of the Immune Response in Age-Dependent Resistance of Mice to Encephalitis Due to Sindbis Virus</article-title><source>J. Infect. Dis.</source><year>1976</year><volume>133</volume><fpage>456</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1093/infdis/133.4.456</pub-id><pub-id pub-id-type="pmid">1262711</pub-id>
</element-citation></ref><ref id="B80-viruses-17-00261"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>R.M.</given-names></name>
<name><surname>Hurlbut</surname><given-names>H.S.</given-names></name>
<name><surname>Work</surname><given-names>T.H.</given-names></name>
<name><surname>Kingston</surname><given-names>J.R.</given-names></name>
<name><surname>Frothingham</surname><given-names>T.E.</given-names></name>
</person-group><article-title>Sindbis Virus: A Newly Recognized Arthropodtransmitted Virus</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1955</year><volume>4</volume><fpage>844</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1955.4.844</pub-id><pub-id pub-id-type="pmid">13259009</pub-id>
</element-citation></ref><ref id="B81-viruses-17-00261"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levine</surname><given-names>B.</given-names></name>
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Molecular Analysis of Neurovirulent Strains of Sindbis Virus That Evolve during Persistent Infection of Scid Mice</article-title><source>J. Virol.</source><year>1993</year><volume>67</volume><fpage>6872</fpage><lpage>6875</lpage><pub-id pub-id-type="doi">10.1128/jvi.67.11.6872-6875.1993</pub-id><pub-id pub-id-type="pmid">8411391</pub-id>
</element-citation></ref><ref id="B82-viruses-17-00261"><label>82.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Molecular Pathogenesis of Sindbis Virus Encephalitis in Experimental Animals</article-title><source>Advances in Virus Research</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>1989</year><volume>Volume 36</volume><fpage>255</fpage><lpage>271</lpage><isbn>978-0-12-039836-2</isbn></element-citation></ref><ref id="B83-viruses-17-00261"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
<name><surname>Johnson</surname><given-names>R.T.</given-names></name>
</person-group><article-title>Role of the Immune Response in Recovery from Sindbis Virus Encephalitis in Mice</article-title><source>J. Immunol.</source><year>1977</year><volume>118</volume><fpage>1070</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.118.3.1070</pub-id><pub-id pub-id-type="pmid">845432</pub-id>
</element-citation></ref><ref id="B84-viruses-17-00261"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gates</surname><given-names>M.C.</given-names></name>
<name><surname>Sheahan</surname><given-names>B.J.</given-names></name>
<name><surname>Atkins</surname><given-names>G.J.</given-names></name>
</person-group><article-title>The Pathogenicity of the M9 Mutant of Semliki Forest Virus in Immune-Compromised Mice</article-title><source>J. Gen. Virol.</source><year>1984</year><volume>65</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-65-1-73</pub-id><pub-id pub-id-type="pmid">6319575</pub-id>
</element-citation></ref><ref id="B85-viruses-17-00261"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>W.R.</given-names></name>
<name><surname>Blakemore</surname><given-names>W.F.</given-names></name>
<name><surname>Jagelman</surname><given-names>S.</given-names></name>
<name><surname>Webb</surname><given-names>H.E.</given-names></name>
</person-group><article-title>Demyelination induced in mice by avirulent Semliki Forest virus. II. An ultrastructural study of focal demyelination in the brain</article-title><source>Neuropathol. Appl. Neurobiol.</source><year>1982</year><volume>8</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.1982.tb00256.x</pub-id><pub-id pub-id-type="pmid">6280089</pub-id>
</element-citation></ref><ref id="B86-viruses-17-00261"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amor</surname><given-names>S.</given-names></name>
<name><surname>Scallan</surname><given-names>M.F.</given-names></name>
<name><surname>Morris</surname><given-names>M.M.</given-names></name>
<name><surname>Dyson</surname><given-names>H.</given-names></name>
<name><surname>Fazakerley</surname><given-names>J.K.</given-names></name>
</person-group><article-title>Role of Immune Responses in Protection and Pathogenesis during Semliki Forest Virus Encephalitis</article-title><source>J. Gen. Virol.</source><year>1996</year><volume>77</volume><issue-part>Pt 2</issue-part><fpage>281</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-77-2-281</pub-id><pub-id pub-id-type="pmid">8627232</pub-id>
</element-citation></ref><ref id="B87-viruses-17-00261"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soilu-H&#x000e4;nninen</surname><given-names>M.</given-names></name>
<name><surname>Er&#x000e4;linna</surname><given-names>J.P.</given-names></name>
<name><surname>Hukkanen</surname><given-names>V.</given-names></name>
<name><surname>R&#x000f6;ytt&#x000e4;</surname><given-names>M.</given-names></name>
<name><surname>Salmi</surname><given-names>A.A.</given-names></name>
<name><surname>Salonen</surname><given-names>R.</given-names></name>
</person-group><article-title>Semliki Forest Virus Infects Mouse Brain Endothelial Cells and Causes Blood-Brain Barrier Damage</article-title><source>J. Virol.</source><year>1994</year><volume>68</volume><fpage>6291</fpage><lpage>6298</lpage><pub-id pub-id-type="doi">10.1128/jvi.68.10.6291-6298.1994</pub-id><pub-id pub-id-type="pmid">7916058</pub-id>
</element-citation></ref><ref id="B88-viruses-17-00261"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baxter</surname><given-names>V.K.</given-names></name>
<name><surname>Heise</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Genetic Control of Alphavirus Pathogenesis</article-title><source>Mamm. Genome</source><year>2018</year><volume>29</volume><fpage>408</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1007/s00335-018-9776-1</pub-id><pub-id pub-id-type="pmid">30151711</pub-id>
</element-citation></ref><ref id="B89-viruses-17-00261"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suckling</surname><given-names>A.J.</given-names></name>
<name><surname>Jagelman</surname><given-names>S.</given-names></name>
<name><surname>Illavia</surname><given-names>S.J.</given-names></name>
<name><surname>Webb</surname><given-names>H.E.</given-names></name>
</person-group><article-title>The Effect of Mouse Strain on the Pathogenesis of the Encephalitis and Demyelination Induced by Avirulent Semliki Forest Virus Infections</article-title><source>Br. J. Exp. Pathol.</source><year>1980</year><volume>61</volume><fpage>281</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">6252935</pub-id>
</element-citation></ref><ref id="B90-viruses-17-00261"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thach</surname><given-names>D.C.</given-names></name>
<name><surname>Kleeberger</surname><given-names>S.R.</given-names></name>
<name><surname>Tucker</surname><given-names>P.C.</given-names></name>
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Genetic Control of Neuroadapted Sindbis Virus Replication in Female Mice Maps to Chromosome 2 and Associates with Paralysis and Mortality</article-title><source>J. Virol.</source><year>2001</year><volume>75</volume><fpage>8674</fpage><lpage>8680</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.18.8674-8680.2001</pub-id><pub-id pub-id-type="pmid">11507212</pub-id>
</element-citation></ref><ref id="B91-viruses-17-00261"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dubuisson</surname><given-names>J.</given-names></name>
<name><surname>Lustig</surname><given-names>S.</given-names></name>
<name><surname>Ruggli</surname><given-names>N.</given-names></name>
<name><surname>Akov</surname><given-names>Y.</given-names></name>
<name><surname>Rice</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Genetic Determinants of Sindbis Virus Neuroinvasiveness</article-title><source>J. Virol.</source><year>1997</year><volume>71</volume><fpage>2636</fpage><lpage>2646</lpage><pub-id pub-id-type="doi">10.1128/jvi.71.4.2636-2646.1997</pub-id><pub-id pub-id-type="pmid">9060616</pub-id>
</element-citation></ref><ref id="B92-viruses-17-00261"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lustig</surname><given-names>S.</given-names></name>
<name><surname>Halevy</surname><given-names>M.</given-names></name>
<name><surname>Ben-Nathan</surname><given-names>D.</given-names></name>
<name><surname>Akov</surname><given-names>Y.</given-names></name>
</person-group><article-title>A Novel Variant of Sindbis Virus Is Both Neurovirulent and Neuroinvasive in Adult Mice</article-title><source>Arch. Virol.</source><year>1992</year><volume>122</volume><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1007/BF01317186</pub-id><pub-id pub-id-type="pmid">1346243</pub-id>
</element-citation></ref><ref id="B93-viruses-17-00261"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferguson</surname><given-names>M.C.</given-names></name>
<name><surname>Saul</surname><given-names>S.</given-names></name>
<name><surname>Fragkoudis</surname><given-names>R.</given-names></name>
<name><surname>Weisheit</surname><given-names>S.</given-names></name>
<name><surname>Cox</surname><given-names>J.</given-names></name>
<name><surname>Patabendige</surname><given-names>A.</given-names></name>
<name><surname>Sherwood</surname><given-names>K.</given-names></name>
<name><surname>Watson</surname><given-names>M.</given-names></name>
<name><surname>Merits</surname><given-names>A.</given-names></name>
<name><surname>Fazakerley</surname><given-names>J.K.</given-names></name>
</person-group><article-title>Ability of the Encephalitic Arbovirus Semliki Forest Virus To Cross the Blood-Brain Barrier Is Determined by the Charge of the E2 Glycoprotein</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>7536</fpage><lpage>7549</lpage><pub-id pub-id-type="doi">10.1128/JVI.03645-14</pub-id><pub-id pub-id-type="pmid">25972559</pub-id>
</element-citation></ref><ref id="B94-viruses-17-00261"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Oliveira Souza</surname><given-names>R.</given-names></name>
<name><surname>Duarte J&#x000fa;nior</surname><given-names>J.W.B.</given-names></name>
<name><surname>Della Casa</surname><given-names>V.S.</given-names></name>
<name><surname>Santoro Rosa</surname><given-names>D.</given-names></name>
<name><surname>Renia</surname><given-names>L.</given-names></name>
<name><surname>Claser</surname><given-names>C.</given-names></name>
</person-group><article-title>Unraveling the Complex Interplay: Immunopathology and Immune Evasion Strategies of Alphaviruses with Emphasis on Neurological Implications</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2024</year><volume>14</volume><elocation-id>1421571</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2024.1421571</pub-id><pub-id pub-id-type="pmid">39211797</pub-id>
</element-citation></ref><ref id="B95-viruses-17-00261"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
</person-group><article-title>Innate Immune Evasion by Alphaviruses</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1005586</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1005586</pub-id><pub-id pub-id-type="pmid">36172361</pub-id>
</element-citation></ref><ref id="B96-viruses-17-00261"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gall</surname><given-names>B.</given-names></name>
<name><surname>Pryke</surname><given-names>K.</given-names></name>
<name><surname>Abraham</surname><given-names>J.</given-names></name>
<name><surname>Mizuno</surname><given-names>N.</given-names></name>
<name><surname>Botto</surname><given-names>S.</given-names></name>
<name><surname>Sali</surname><given-names>T.M.</given-names></name>
<name><surname>Broeckel</surname><given-names>R.</given-names></name>
<name><surname>Haese</surname><given-names>N.</given-names></name>
<name><surname>Nilsen</surname><given-names>A.</given-names></name>
<name><surname>Placzek</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Emerging Alphaviruses Are Sensitive to Cellular States Induced by a Novel Small-Molecule Agonist of the STING Pathway</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e01913-17</fpage><pub-id pub-id-type="doi">10.1128/JVI.01913-17</pub-id><pub-id pub-id-type="pmid">29263267</pub-id>
</element-citation></ref><ref id="B97-viruses-17-00261"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gardner</surname><given-names>J.</given-names></name>
<name><surname>Anraku</surname><given-names>I.</given-names></name>
<name><surname>Le</surname><given-names>T.T.</given-names></name>
<name><surname>Larcher</surname><given-names>T.</given-names></name>
<name><surname>Major</surname><given-names>L.</given-names></name>
<name><surname>Roques</surname><given-names>P.</given-names></name>
<name><surname>Schroder</surname><given-names>W.A.</given-names></name>
<name><surname>Higgs</surname><given-names>S.</given-names></name>
<name><surname>Suhrbier</surname><given-names>A.</given-names></name>
</person-group><article-title>Chikungunya Virus Arthritis in Adult Wild-Type Mice</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>8021</fpage><lpage>8032</lpage><pub-id pub-id-type="doi">10.1128/JVI.02603-09</pub-id><pub-id pub-id-type="pmid">20519386</pub-id>
</element-citation></ref><ref id="B98-viruses-17-00261"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rowell</surname><given-names>J.F.</given-names></name>
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Contribution of T Cells to Mortality in Neurovirulent Sindbis Virus Encephalomyelitis</article-title><source>J. Neuroimmunol.</source><year>2002</year><volume>127</volume><fpage>106</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(02)00108-X</pub-id><pub-id pub-id-type="pmid">12044981</pub-id>
</element-citation></ref><ref id="B99-viruses-17-00261"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baxter</surname><given-names>V.K.</given-names></name>
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Interferon-Gamma Modulation of the Local T Cell Response to Alphavirus Encephalomyelitis</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>113</elocation-id><pub-id pub-id-type="doi">10.3390/v12010113</pub-id><pub-id pub-id-type="pmid">31963302</pub-id>
</element-citation></ref><ref id="B100-viruses-17-00261"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thach</surname><given-names>D.C.</given-names></name>
<name><surname>Kimura</surname><given-names>T.</given-names></name>
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Differences between C57BL/6 and BALB/cBy Mice in Mortality and Virus Replication after Intranasal Infection with Neuroadapted Sindbis Virus</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>6156</fpage><lpage>6161</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.13.6156-6161.2000</pub-id><pub-id pub-id-type="pmid">10846099</pub-id>
</element-citation></ref><ref id="B101-viruses-17-00261"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seay</surname><given-names>A.R.</given-names></name>
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
<name><surname>Johnson</surname><given-names>R.T.</given-names></name>
</person-group><article-title>Experimental Viral Polymyositis: Age Dependency and Immune Responses to Ross River Virus Infection in Mice</article-title><source>Neurology</source><year>1981</year><volume>31</volume><fpage>656</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1212/WNL.31.6.656</pub-id><pub-id pub-id-type="pmid">6264346</pub-id>
</element-citation></ref><ref id="B102-viruses-17-00261"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rueda</surname><given-names>J.C.</given-names></name>
<name><surname>Arcos-Burgos</surname><given-names>M.</given-names></name>
<name><surname>Santos</surname><given-names>A.M.</given-names></name>
<name><surname>Martin-Arsanios</surname><given-names>D.</given-names></name>
<name><surname>Villota-Erazo</surname><given-names>C.</given-names></name>
<name><surname>Reyes</surname><given-names>V.</given-names></name>
<name><surname>Bernal-Mac&#x000ed;as</surname><given-names>S.</given-names></name>
<name><surname>Pel&#x000e1;ez-Ballestas</surname><given-names>I.</given-names></name>
<name><surname>Cardiel</surname><given-names>M.H.</given-names></name>
<name><surname>Londono</surname><given-names>J.</given-names></name>
</person-group><article-title>Human Genetic Host Factors and Its Role in the Pathogenesis of Chikungunya Virus Infection</article-title><source>Front. Med.</source><year>2022</year><volume>9</volume><elocation-id>654395</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2022.654395</pub-id></element-citation></ref><ref id="B103-viruses-17-00261"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seay</surname><given-names>A.R.</given-names></name>
<name><surname>Wolinsky</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Ross River Virus-induced Demyelination: I. Pathogenesis and Histopathology</article-title><source>Ann. Neurol.</source><year>1982</year><volume>12</volume><fpage>380</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1002/ana.410120411</pub-id><pub-id pub-id-type="pmid">6293370</pub-id>
</element-citation></ref><ref id="B104-viruses-17-00261"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tucker</surname><given-names>P.C.</given-names></name>
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
<name><surname>Choi</surname><given-names>S.</given-names></name>
<name><surname>Bui</surname><given-names>N.</given-names></name>
<name><surname>Wesselingh</surname><given-names>S.</given-names></name>
</person-group><article-title>Inhibition of Nitric Oxide Synthesis Increases Mortality in Sindbis Virus Encephalitis</article-title><source>J. Virol.</source><year>1996</year><volume>70</volume><fpage>3972</fpage><lpage>3977</lpage><pub-id pub-id-type="doi">10.1128/jvi.70.6.3972-3977.1996</pub-id><pub-id pub-id-type="pmid">8648734</pub-id>
</element-citation></ref><ref id="B105-viruses-17-00261"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kulcsar</surname><given-names>K.A.</given-names></name>
<name><surname>Baxter</surname><given-names>V.K.</given-names></name>
<name><surname>Abraham</surname><given-names>R.</given-names></name>
<name><surname>Nelson</surname><given-names>A.</given-names></name>
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Distinct Immune Responses in Resistant and Susceptible Strains of Mice during Neurovirulent Alphavirus Encephalomyelitis</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>8280</fpage><lpage>8291</lpage><pub-id pub-id-type="doi">10.1128/JVI.00173-15</pub-id><pub-id pub-id-type="pmid">26041298</pub-id>
</element-citation></ref><ref id="B106-viruses-17-00261"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000fc;ler</surname><given-names>M.L.</given-names></name>
<name><surname>Gorham</surname><given-names>J.D.</given-names></name>
<name><surname>Hsieh</surname><given-names>C.-S.</given-names></name>
<name><surname>Mackey</surname><given-names>A.J.</given-names></name>
<name><surname>Steen</surname><given-names>R.G.</given-names></name>
<name><surname>Dietrich</surname><given-names>W.F.</given-names></name>
<name><surname>Murphy</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Genetic Susceptibility to Leishmania: IL-12 Responsiveness in TH1 Cell Development</article-title><source>Science</source><year>1996</year><volume>271</volume><fpage>984</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1126/science.271.5251.984</pub-id><pub-id pub-id-type="pmid">8584935</pub-id>
</element-citation></ref><ref id="B107-viruses-17-00261"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mosmann</surname><given-names>T.R.</given-names></name>
<name><surname>Coffman</surname><given-names>R.L.</given-names></name>
</person-group><article-title>TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties</article-title><source>Annu. Rev. Immunol.</source><year>1989</year><volume>7</volume><fpage>145</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1146/annurev.iy.07.040189.001045</pub-id><pub-id pub-id-type="pmid">2523712</pub-id>
</element-citation></ref><ref id="B108-viruses-17-00261"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Posadas-Mondrag&#x000f3;n</surname><given-names>A.</given-names></name>
<name><surname>Santiago-Cruz</surname><given-names>J.A.</given-names></name>
<name><surname>P&#x000e9;rez-Ju&#x000e1;rez</surname><given-names>A.</given-names></name>
<name><surname>Herrera-Gonz&#x000e1;lez</surname><given-names>N.E.</given-names></name>
<name><surname>Sosa-Delgado</surname><given-names>S.M.</given-names></name>
<name><surname>Wong-Ar&#x000e1;mbula</surname><given-names>C.E.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Maldonado</surname><given-names>A.P.</given-names></name>
<name><surname>V&#x000e1;zquez-Pichardo</surname><given-names>M.</given-names></name>
<name><surname>Duran-Ayala</surname><given-names>D.</given-names></name>
<name><surname>Aguilar-Faisal</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Cross-Neutralizing Anti-Chikungunya and Anti-Dengue 2 IgG Antibodies from Patients and BALB/c Mice against Dengue and Chikungunya Viruses</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>1098</elocation-id><pub-id pub-id-type="doi">10.3390/v16071098</pub-id><pub-id pub-id-type="pmid">39066260</pub-id>
</element-citation></ref><ref id="B109-viruses-17-00261"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Islam</surname><given-names>M.A.</given-names></name>
<name><surname>Zowalaty</surname><given-names>M.E.E.</given-names></name>
<name><surname>Islam</surname><given-names>S.</given-names></name>
<name><surname>Sharif</surname><given-names>M.</given-names></name>
<name><surname>Rahman</surname><given-names>M.R.</given-names></name>
<name><surname>Amin</surname><given-names>M.R.</given-names></name>
<name><surname>Ali</surname><given-names>M.M.</given-names></name>
<name><surname>Rahman</surname><given-names>M.T.</given-names></name>
<name><surname>Morita</surname><given-names>K.</given-names></name>
<name><surname>Ashour</surname><given-names>H.M.</given-names></name>
</person-group><article-title>A Novel Multiplex RT-PCR Assay for Simultaneous Detection of Dengue and Chikungunya Viruses</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>8281</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21218281</pub-id><pub-id pub-id-type="pmid">33167379</pub-id>
</element-citation></ref><ref id="B110-viruses-17-00261"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gardner</surname><given-names>C.L.</given-names></name>
<name><surname>Burke</surname><given-names>C.W.</given-names></name>
<name><surname>Higgs</surname><given-names>S.T.</given-names></name>
<name><surname>Klimstra</surname><given-names>W.B.</given-names></name>
<name><surname>Ryman</surname><given-names>K.D.</given-names></name>
</person-group><article-title>Interferon-Alpha/Beta Deficiency Greatly Exacerbates Arthritogenic Disease in Mice Infected with Wild-Type Chikungunya Virus but Not with the Cell Culture-Adapted Live-Attenuated 181/25 Vaccine Candidate</article-title><source>Virology</source><year>2012</year><volume>425</volume><fpage>103</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2011.12.020</pub-id><pub-id pub-id-type="pmid">22305131</pub-id>
</element-citation></ref><ref id="B111-viruses-17-00261"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burdeinick-Kerr</surname><given-names>R.</given-names></name>
<name><surname>Wind</surname><given-names>J.</given-names></name>
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Synergistic Roles of Antibody and Interferon in Noncytolytic Clearance of Sindbis Virus from Different Regions of the Central Nervous System</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>5628</fpage><lpage>5636</lpage><pub-id pub-id-type="doi">10.1128/JVI.01152-06</pub-id><pub-id pub-id-type="pmid">17376910</pub-id>
</element-citation></ref><ref id="B112-viruses-17-00261"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lidbury</surname><given-names>B.A.</given-names></name>
<name><surname>Simeonovic</surname><given-names>C.</given-names></name>
<name><surname>Maxwell</surname><given-names>G.E.</given-names></name>
<name><surname>Marshall</surname><given-names>I.D.</given-names></name>
<name><surname>Hapel</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Macrophage-Induced Muscle Pathology Results in Morbidity and Mortality for Ross River Virus&#x02013;Infected Mice</article-title><source>J. Infect. Dis.</source><year>2000</year><volume>181</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1086/315164</pub-id><pub-id pub-id-type="pmid">10608747</pub-id>
</element-citation></ref><ref id="B113-viruses-17-00261"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eaton</surname><given-names>B.T.</given-names></name>
<name><surname>Hapel</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Persistent Noncytolytic Togavirus Infection of Primary Mouse Muscle Cells</article-title><source>Virology</source><year>1976</year><volume>72</volume><fpage>266</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(76)90329-9</pub-id><pub-id pub-id-type="pmid">945639</pub-id>
</element-citation></ref><ref id="B114-viruses-17-00261"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikitina</surname><given-names>E.</given-names></name>
<name><surname>Larionova</surname><given-names>I.</given-names></name>
<name><surname>Choinzonov</surname><given-names>E.</given-names></name>
<name><surname>Kzhyshkowska</surname><given-names>J.</given-names></name>
</person-group><article-title>Monocytes and Macrophages as Viral Targets and Reservoirs</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>2821</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19092821</pub-id><pub-id pub-id-type="pmid">30231586</pub-id>
</element-citation></ref><ref id="B115-viruses-17-00261"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baxter</surname><given-names>V.K.</given-names></name>
<name><surname>Griffin</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Interferon Gamma Modulation of Disease Manifestation and the Local Antibody Response to Alphavirus Encephalomyelitis</article-title><source>J. Gen. Virol.</source><year>2016</year><volume>97</volume><fpage>2908</fpage><lpage>2925</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.000613</pub-id><pub-id pub-id-type="pmid">27667782</pub-id>
</element-citation></ref><ref id="B116-viruses-17-00261"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Subak-Sharpe</surname><given-names>I.</given-names></name>
<name><surname>Dyson</surname><given-names>H.</given-names></name>
<name><surname>Fazakerley</surname><given-names>J.</given-names></name>
</person-group><article-title>In Vivo Depletion of CD8+ T Cells Prevents Lesions of Demyelination in Semliki Forest Virus Infection</article-title><source>J. Virol.</source><year>1993</year><volume>67</volume><fpage>7629</fpage><lpage>7633</lpage><pub-id pub-id-type="doi">10.1128/jvi.67.12.7629-7633.1993</pub-id><pub-id pub-id-type="pmid">7901429</pub-id>
</element-citation></ref><ref id="B117-viruses-17-00261"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morrison</surname><given-names>T.E.</given-names></name>
<name><surname>Simmons</surname><given-names>J.D.</given-names></name>
<name><surname>Heise</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Complement Receptor 3 Promotes Severe Ross River Virus-Induced Disease</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>11263</fpage><lpage>11272</lpage><pub-id pub-id-type="doi">10.1128/JVI.01352-08</pub-id><pub-id pub-id-type="pmid">18787004</pub-id>
</element-citation></ref><ref id="B118-viruses-17-00261"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>M.</given-names></name>
<name><surname>Narciso-Abraham</surname><given-names>M.</given-names></name>
<name><surname>Hadl</surname><given-names>S.</given-names></name>
<name><surname>McMahon</surname><given-names>R.</given-names></name>
<name><surname>Toepfer</surname><given-names>S.</given-names></name>
<name><surname>Fuchs</surname><given-names>U.</given-names></name>
<name><surname>Hochreiter</surname><given-names>R.</given-names></name>
<name><surname>Bitzer</surname><given-names>A.</given-names></name>
<name><surname>Kosulin</surname><given-names>K.</given-names></name>
<name><surname>Larcher-Senn</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Safety and Immunogenicity of a Single-Shot Live-Attenuated Chikungunya Vaccine: A Double-Blind, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial</article-title><source>Lancet Lond. Engl.</source><year>2023</year><volume>401</volume><fpage>2138</fpage><lpage>2147</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)00641-4</pub-id></element-citation></ref><ref id="B119-viruses-17-00261"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wressnigg</surname><given-names>N.</given-names></name>
<name><surname>van der Velden</surname><given-names>M.V.W.</given-names></name>
<name><surname>Portsmouth</surname><given-names>D.</given-names></name>
<name><surname>Draxler</surname><given-names>W.</given-names></name>
<name><surname>O&#x02019;Rourke</surname><given-names>M.</given-names></name>
<name><surname>Richmond</surname><given-names>P.</given-names></name>
<name><surname>Hall</surname><given-names>S.</given-names></name>
<name><surname>McBride</surname><given-names>W.J.H.</given-names></name>
<name><surname>Redfern</surname><given-names>A.</given-names></name>
<name><surname>Aaskov</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>An Inactivated Ross River Virus Vaccine Is Well Tolerated and Immunogenic in an Adult Population in a Randomized Phase 3 Trial</article-title><source>Clin. Vaccine Immunol. CVI</source><year>2015</year><volume>22</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1128/CVI.00546-14</pub-id><pub-id pub-id-type="pmid">25540268</pub-id>
</element-citation></ref><ref id="B120-viruses-17-00261"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Puhl</surname><given-names>A.C.</given-names></name>
<name><surname>Fernandes</surname><given-names>R.S.</given-names></name>
<name><surname>Godoy</surname><given-names>A.S.</given-names></name>
<name><surname>Gil</surname><given-names>L.H.V.G.</given-names></name>
<name><surname>Oliva</surname><given-names>G.</given-names></name>
<name><surname>Ekins</surname><given-names>S.</given-names></name>
</person-group><article-title>The Protein Disulfide Isomerase Inhibitor 3-Methyltoxoflavin Inhibits Chikungunya Virus</article-title><source>Bioorg. Med. Chem.</source><year>2023</year><volume>83</volume><elocation-id>117239</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmc.2023.117239</pub-id><pub-id pub-id-type="pmid">36940609</pub-id>
</element-citation></ref><ref id="B121-viruses-17-00261"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hucke</surname><given-names>F.I.L.</given-names></name>
<name><surname>Bugert</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Current and Promising Antivirals Against Chikungunya Virus</article-title><source>Front. Public Health</source><year>2020</year><volume>8</volume><elocation-id>618624</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2020.618624</pub-id><pub-id pub-id-type="pmid">33384981</pub-id>
</element-citation></ref><ref id="B122-viruses-17-00261"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Battisti</surname><given-names>V.</given-names></name>
<name><surname>Urban</surname><given-names>E.</given-names></name>
<name><surname>Langer</surname><given-names>T.</given-names></name>
</person-group><article-title>Antivirals against the Chikungunya Virus</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1307</elocation-id><pub-id pub-id-type="doi">10.3390/v13071307</pub-id><pub-id pub-id-type="pmid">34372513</pub-id>
</element-citation></ref><ref id="B123-viruses-17-00261"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Delogu</surname><given-names>I.</given-names></name>
<name><surname>De Lamballerie</surname><given-names>X.</given-names></name>
</person-group><article-title>Chikungunya Disease and Chloroquine Treatment</article-title><source>J. Med. Virol.</source><year>2011</year><volume>83</volume><fpage>1058</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1002/jmv.22019</pub-id><pub-id pub-id-type="pmid">21503920</pub-id>
</element-citation></ref><ref id="B124-viruses-17-00261"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>FERREIRA</surname><given-names>D.F.</given-names></name>
<name><surname>SANTO</surname><given-names>M.P.E.</given-names></name>
<name><surname>REBELLO</surname><given-names>M.A.</given-names></name>
<name><surname>REBELLO</surname><given-names>M.C.S.</given-names></name>
</person-group><article-title>Weak Bases Affect Late Stages of Mayaro Virus Replication Cycle in Vertebrate Cells</article-title><source>J. Med. Microbiol.</source><year>2000</year><volume>49</volume><fpage>313</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-49-4-313</pub-id><pub-id pub-id-type="pmid">10755624</pub-id>
</element-citation></ref><ref id="B125-viruses-17-00261"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fox</surname><given-names>J.M.</given-names></name>
<name><surname>Long</surname><given-names>F.</given-names></name>
<name><surname>Edeling</surname><given-names>M.A.</given-names></name>
<name><surname>Lin</surname><given-names>H.</given-names></name>
<name><surname>van Duijl-Richter</surname><given-names>M.K.S.</given-names></name>
<name><surname>Fong</surname><given-names>R.H.</given-names></name>
<name><surname>Kahle</surname><given-names>K.M.</given-names></name>
<name><surname>Smit</surname><given-names>J.M.</given-names></name>
<name><surname>Jin</surname><given-names>J.</given-names></name>
<name><surname>Simmons</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>1095</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.050</pub-id><pub-id pub-id-type="pmid">26553503</pub-id>
</element-citation></ref><ref id="B126-viruses-17-00261"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>Y.B.</given-names></name>
<name><surname>Lee</surname><given-names>H.-J.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Poo</surname><given-names>H.</given-names></name>
</person-group><article-title>Development of a Specific CHIKV-E2 Monoclonal Antibody for Chikungunya Diagnosis</article-title><source>Virol. Sin.</source><year>2019</year><volume>34</volume><fpage>563</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1007/s12250-019-00135-y</pub-id><pub-id pub-id-type="pmid">31214999</pub-id>
</element-citation></ref><ref id="B127-viruses-17-00261"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quiroz</surname><given-names>J.A.</given-names></name>
<name><surname>Malonis</surname><given-names>R.J.</given-names></name>
<name><surname>Thackray</surname><given-names>L.B.</given-names></name>
<name><surname>Cohen</surname><given-names>C.A.</given-names></name>
<name><surname>Pallesen</surname><given-names>J.</given-names></name>
<name><surname>Jangra</surname><given-names>R.K.</given-names></name>
<name><surname>Brown</surname><given-names>R.S.</given-names></name>
<name><surname>Hofmann</surname><given-names>D.</given-names></name>
<name><surname>Holtsberg</surname><given-names>F.W.</given-names></name>
<name><surname>Shulenin</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Human Monoclonal Antibodies against Chikungunya Virus Target Multiple Distinct Epitopes in the E1 and E2 Glycoproteins</article-title><source>PLoS Pathog.</source><year>2019</year><volume>15</volume><elocation-id>e1008061</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008061</pub-id><pub-id pub-id-type="pmid">31697791</pub-id>
</element-citation></ref><ref id="B128-viruses-17-00261"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fox</surname><given-names>J.M.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Tahan</surname><given-names>S.</given-names></name>
<name><surname>Powell</surname><given-names>L.A.</given-names></name>
<name><surname>Crowe</surname><given-names>J.E.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Diamond</surname><given-names>M.S.</given-names></name>
</person-group><article-title>A Cross-Reactive Antibody Protects against Ross River Virus Musculoskeletal Disease despite Rapid Neutralization Escape in Mice</article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><elocation-id>e1008743</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008743</pub-id><pub-id pub-id-type="pmid">32760128</pub-id>
</element-citation></ref><ref id="B129-viruses-17-00261"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>August</surname><given-names>A.</given-names></name>
<name><surname>Attarwala</surname><given-names>H.Z.</given-names></name>
<name><surname>Himansu</surname><given-names>S.</given-names></name>
<name><surname>Kalidindi</surname><given-names>S.</given-names></name>
<name><surname>Lu</surname><given-names>S.</given-names></name>
<name><surname>Pajon</surname><given-names>R.</given-names></name>
<name><surname>Han</surname><given-names>S.</given-names></name>
<name><surname>Lecerf</surname><given-names>J.-M.</given-names></name>
<name><surname>Tomassini</surname><given-names>J.E.</given-names></name>
<name><surname>Hard</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>A Phase 1 Trial of Lipid-Encapsulated mRNA Encoding a Monoclonal Antibody with Neutralizing Activity against Chikungunya Virus</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>2224</fpage><lpage>2233</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01573-6</pub-id><pub-id pub-id-type="pmid">34887572</pub-id>
</element-citation></ref><ref id="B130-viruses-17-00261"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Savithri Nandeesha</surname><given-names>S.</given-names></name>
<name><surname>Kasagga</surname><given-names>A.</given-names></name>
<name><surname>Hawrami</surname><given-names>C.</given-names></name>
<name><surname>Ricci</surname><given-names>E.</given-names></name>
<name><surname>Hailu</surname><given-names>K.T.</given-names></name>
<name><surname>Salib</surname><given-names>K.</given-names></name>
<name><surname>Butt</surname><given-names>S.</given-names></name>
</person-group><article-title>Treatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barr&#x000e9; Syndrome Management: A Systematic Review</article-title><source>Cureus</source><year>2024</year><volume>16</volume><fpage>e57066</fpage><pub-id pub-id-type="doi">10.7759/cureus.57066</pub-id><pub-id pub-id-type="pmid">38681292</pub-id>
</element-citation></ref><ref id="B131-viruses-17-00261"><label>131.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
<collab>UNICEF</collab>
<collab>UNDP</collab>
<collab>World Bank</collab>
</person-group><source>WHO Special Programme for Research and Training in Tropical Diseases Global Vector Control Response 2017&#x02013;2030</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2017</year></element-citation></ref><ref id="B132-viruses-17-00261"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balakrishnan</surname><given-names>V.S.</given-names></name>
</person-group><article-title>WHO Launches Global Initiative for Arboviral Diseases</article-title><source>Lancet Microbe</source><year>2022</year><volume>3</volume><fpage>e407</fpage><pub-id pub-id-type="doi">10.1016/S2666-5247(22)00130-6</pub-id><pub-id pub-id-type="pmid">35659901</pub-id>
</element-citation></ref><ref id="B133-viruses-17-00261"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ly</surname><given-names>H.</given-names></name>
</person-group><article-title>Ixchiq (VLA1553): The First FDA-Approved Vaccine to Prevent Disease Caused by Chikungunya Virus Infection</article-title><source>Virulence</source><year>2024</year><volume>15</volume><fpage>2301573</fpage><pub-id pub-id-type="doi">10.1080/21505594.2023.2301573</pub-id><pub-id pub-id-type="pmid">38217381</pub-id>
</element-citation></ref><ref id="B134-viruses-17-00261"><label>134.</label><element-citation publication-type="webpage"><article-title>Valneva Announces Health Canada Approval of the World&#x02019;s First Chikungunya Vaccine, IXCHIQ<sup>&#x000ae;</sup></article-title><comment>Available online: <ext-link xlink:href="https://valneva.com/press-release/valneva-announces-health-canada-approval-of-the-worlds-first-chikungunya-vaccine-ixchiq/" ext-link-type="uri">https://valneva.com/press-release/valneva-announces-health-canada-approval-of-the-worlds-first-chikungunya-vaccine-ixchiq/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-20">(accessed on 20 November 2024)</date-in-citation></element-citation></ref><ref id="B135-viruses-17-00261"><label>135.</label><element-citation publication-type="webpage"><article-title>Valneva Receives Marketing Authorization in Europe for the World&#x02019;s First Chikungunya Vaccine, IXCHIQ<sup>&#x000ae;</sup></article-title><comment>Available online: <ext-link xlink:href="https://valneva.com/press-release/valneva-receives-marketing-authorization-in-europe-for-the-worlds-first-chikungunya-vaccine-ixchiq/" ext-link-type="uri">https://valneva.com/press-release/valneva-receives-marketing-authorization-in-europe-for-the-worlds-first-chikungunya-vaccine-ixchiq/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-20">(accessed on 20 November 2024)</date-in-citation></element-citation></ref><ref id="B136-viruses-17-00261"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Halleng&#x000e4;rd</surname><given-names>D.</given-names></name>
<name><surname>Kakoulidou</surname><given-names>M.</given-names></name>
<name><surname>Lulla</surname><given-names>A.</given-names></name>
<name><surname>K&#x000fc;mmerer</surname><given-names>B.M.</given-names></name>
<name><surname>Johansson</surname><given-names>D.X.</given-names></name>
<name><surname>Mutso</surname><given-names>M.</given-names></name>
<name><surname>Lulla</surname><given-names>V.</given-names></name>
<name><surname>Fazakerley</surname><given-names>J.K.</given-names></name>
<name><surname>Roques</surname><given-names>P.</given-names></name>
<name><surname>Le Grand</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Novel Attenuated Chikungunya Vaccine Candidates Elicit Protective Immunity in C57BL/6 Mice</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>2858</fpage><lpage>2866</lpage><pub-id pub-id-type="doi">10.1128/JVI.03453-13</pub-id><pub-id pub-id-type="pmid">24371047</pub-id>
</element-citation></ref><ref id="B137-viruses-17-00261"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mota</surname><given-names>M.T.d.O.</given-names></name>
<name><surname>Costa</surname><given-names>V.V.</given-names></name>
<name><surname>Sugimoto</surname><given-names>M.A.</given-names></name>
<name><surname>Guimar&#x000e3;es</surname><given-names>G.d.F.</given-names></name>
<name><surname>Queiroz-Junior</surname><given-names>C.M.</given-names></name>
<name><surname>Moreira</surname><given-names>T.P.</given-names></name>
<name><surname>de Sousa</surname><given-names>C.D.</given-names></name>
<name><surname>Santos</surname><given-names>F.M.</given-names></name>
<name><surname>Queiroz</surname><given-names>V.F.</given-names></name>
<name><surname>Passos</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>In-Depth Characterization of a Novel Live-Attenuated Mayaro Virus Vaccine Candidate Using an Immunocompetent Mouse Model of Mayaro Disease</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>5306</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-62084-x</pub-id><pub-id pub-id-type="pmid">32210270</pub-id>
</element-citation></ref><ref id="B138-viruses-17-00261"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Powers</surname><given-names>J.M.</given-names></name>
<name><surname>Haese</surname><given-names>N.N.</given-names></name>
<name><surname>Denton</surname><given-names>M.</given-names></name>
<name><surname>Ando</surname><given-names>T.</given-names></name>
<name><surname>Kreklywich</surname><given-names>C.</given-names></name>
<name><surname>Bonin</surname><given-names>K.</given-names></name>
<name><surname>Streblow</surname><given-names>C.E.</given-names></name>
<name><surname>Kreklywich</surname><given-names>N.</given-names></name>
<name><surname>Smith</surname><given-names>P.</given-names></name>
<name><surname>Broeckel</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Non-Replicating Adenovirus Based Mayaro Virus Vaccine Elicits Protective Immune Responses and Cross Protects against Other Alphaviruses</article-title><source>PLoS Negl. Trop. Dis.</source><year>2021</year><volume>15</volume><elocation-id>e0009308</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0009308</pub-id><pub-id pub-id-type="pmid">33793555</pub-id>
</element-citation></ref><ref id="B139-viruses-17-00261"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>Y.C.</given-names></name>
<name><surname>L&#x000fc;cke</surname><given-names>A.-C.</given-names></name>
<name><surname>L&#x000f3;pez-Camacho</surname><given-names>C.</given-names></name>
<name><surname>K&#x000fc;mmerer</surname><given-names>B.M.</given-names></name>
<name><surname>Reyes-Sandoval</surname><given-names>A.</given-names></name>
</person-group><article-title>Development of Viral-Vectored Vaccines and Virus Replicon Particle-Based Neutralisation Assay against Mayaro Virus</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>4105</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23084105</pub-id><pub-id pub-id-type="pmid">35456923</pub-id>
</element-citation></ref><ref id="B140-viruses-17-00261"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abbo</surname><given-names>S.R.</given-names></name>
<name><surname>Nguyen</surname><given-names>W.</given-names></name>
<name><surname>Abma-Henkens</surname><given-names>M.H.C.</given-names></name>
<name><surname>van de Kamer</surname><given-names>D.</given-names></name>
<name><surname>Savelkoul</surname><given-names>N.H.A.</given-names></name>
<name><surname>Geertsema</surname><given-names>C.</given-names></name>
<name><surname>Le</surname><given-names>T.T.T.</given-names></name>
<name><surname>Tang</surname><given-names>B.</given-names></name>
<name><surname>Yan</surname><given-names>K.</given-names></name>
<name><surname>Dumenil</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Comparative Efficacy of Mayaro Virus-Like Particle Vaccines Produced in Insect or Mammalian Cells</article-title><source>J. Virol.</source><year>2023</year><volume>97</volume><fpage>e0160122</fpage><pub-id pub-id-type="doi">10.1128/jvi.01601-22</pub-id><pub-id pub-id-type="pmid">36883812</pub-id>
</element-citation></ref><ref id="B141-viruses-17-00261"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Webb</surname><given-names>E.M.</given-names></name>
<name><surname>Azar</surname><given-names>S.R.</given-names></name>
<name><surname>Haller</surname><given-names>S.L.</given-names></name>
<name><surname>Langsjoen</surname><given-names>R.M.</given-names></name>
<name><surname>Cuthbert</surname><given-names>C.E.</given-names></name>
<name><surname>Ramjag</surname><given-names>A.T.</given-names></name>
<name><surname>Luo</surname><given-names>H.</given-names></name>
<name><surname>Plante</surname><given-names>K.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Simmons</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Effects of Chikungunya Virus Immunity on Mayaro Virus Disease and Epidemic Potential</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>20399</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-56551-3</pub-id><pub-id pub-id-type="pmid">31892710</pub-id>
</element-citation></ref><ref id="B142-viruses-17-00261"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Partidos</surname><given-names>C.D.</given-names></name>
<name><surname>Paykel</surname><given-names>J.</given-names></name>
<name><surname>Weger</surname><given-names>J.</given-names></name>
<name><surname>Borland</surname><given-names>E.M.</given-names></name>
<name><surname>Powers</surname><given-names>A.M.</given-names></name>
<name><surname>Seymour</surname><given-names>R.</given-names></name>
<name><surname>Weaver</surname><given-names>S.C.</given-names></name>
<name><surname>Stinchcomb</surname><given-names>D.T.</given-names></name>
<name><surname>Osorio</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Cross-Protective Immunity against o&#x02018;nyong-Nyong Virus Afforded by a Novel Recombinant Chikungunya Vaccine</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>4638</fpage><lpage>4643</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.099</pub-id><pub-id pub-id-type="pmid">22583812</pub-id>
</element-citation></ref><ref id="B143-viruses-17-00261"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdelnabi</surname><given-names>R.</given-names></name>
<name><surname>Delang</surname><given-names>L.</given-names></name>
</person-group><article-title>Antiviral Strategies against Arthritogenic Alphaviruses</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>1365</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8091365</pub-id><pub-id pub-id-type="pmid">32906603</pub-id>
</element-citation></ref><ref id="B144-viruses-17-00261"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guerrero-Arguero</surname><given-names>I.</given-names></name>
<name><surname>Tellez-Freitas</surname><given-names>C.M.</given-names></name>
<name><surname>Weber</surname><given-names>K.S.</given-names></name>
<name><surname>Berges</surname><given-names>B.K.</given-names></name>
<name><surname>Robison</surname><given-names>R.A.</given-names></name>
<name><surname>Pickett</surname><given-names>B.E.</given-names></name>
</person-group><article-title>Alphaviruses: Host Pathogenesis, Immune Response, and Vaccine &#x00026; Treatment Updates</article-title><source>J. Gen. Virol.</source><year>2021</year><volume>102</volume><fpage>001644</fpage><pub-id pub-id-type="doi">10.1099/jgv.0.001644</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-00261-f001"><label>Figure 1</label><caption><p>Alphavirus replication in the host cell, including steps targeted by antivirals, and the antiviral response mounted by the host. This figure was created using biorender.com.</p></caption><graphic xlink:href="viruses-17-00261-g001" position="float"/></fig><table-wrap position="float" id="viruses-17-00261-t001"><object-id pub-id-type="pii">viruses-17-00261-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of case reports of neurological disease for Old World alphaviruses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Location, Year, Ref</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age(s), n Sex</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Neurological Symptoms/Imaging</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Laboratory Testing</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Diagnosis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment,<break/>Outcome</th></tr></thead><tbody><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">CHIKV</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R&#x000e9;union Island, 2006 [<xref rid="B36-viruses-17-00261" ref-type="bibr">36</xref>,<xref rid="B37-viruses-17-00261" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51, F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Bilateral facial palsy</p></list-item><list-item><p>Quadriparesis</p></list-item><list-item><p>Global areflexia</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum positive for anti-CHIKV IgM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GBS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV IgG, <break/>partial recovery</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R&#x000e9;union Island, 2007 [<xref rid="B36-viruses-17-00261" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60, M</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Distal hypoesthesia</p></list-item><list-item><p>Left facial palsy</p></list-item><list-item><p>Quadriparesis</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Serum positive for CHIKV IgM 7 dpa</p></list-item><list-item><p>Serum positive for CHIKV by RT-PCR</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GBS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Switzerland, 2014 (traveler acquired from Tahiti) [<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74, M</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Hypesthesia</p></list-item><list-item><p>Partial paralysis</p></list-item><list-item><p>alpha coma</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum positive for anti-CHIKV IgM/IgG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GBS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">California (traveler acquired from Tonga), 2014 [<xref rid="B39-viruses-17-00261" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57, M</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Reduced level of consciousness</p></list-item><list-item><p>tonic-clonic seizure</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Serum positive RT-PCR</p></list-item><list-item><p>Serum positive for anti-CHIKV IgM/IgG</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Encephalitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Supportive care, Anti-epileptics,<break/>Partial Recovery</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Honduras, 2015 [<xref rid="B40-viruses-17-00261" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;1, <break/>14 M and F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Bulging fontanelle</p></list-item><list-item><p>Mild brain edema</p></list-item><list-item><p>Seizures</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CSF and serum RT-PCR positive for CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Meningo-encephalitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Symptomatic care with NSAIDS,<break/>2 died</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Honduras, 2015 [<xref rid="B41-viruses-17-00261" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28&#x02013;85, <break/>5 M and 2 F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Stupor</p></list-item><list-item><p>Status epilepticus</p></list-item><list-item><p>periventricular lesions</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-CHIKV IgM <break/>negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Encephalitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV acyclovir,<break/>2 F died, others recovered</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India, 2016 [<xref rid="B42-viruses-17-00261" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55, M</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Altered sensorium</p></list-item><list-item><p>Hyperintense lesion in the splenium</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum and CSF RT-PCR positive for CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild <break/>encephalitis with<break/>splenial lesion</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV fluids,<break/>Recovered</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Korea (traveler acquired from Cambodia), 2023 [<xref rid="B43-viruses-17-00261" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40, M</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Vertigo</p></list-item><list-item><p>Confusion</p></list-item><list-item><p>Ataxia</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum was positive for anti-CHIKV IgM 5 dpa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Encephalitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV methylprednisolone, <break/>recovered</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India, 2024 [<xref rid="B44-viruses-17-00261" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12, 1 M</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Decline in consciousness</p></list-item><list-item><p>White matter brain lesions</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CSF and serum RT-PCR positive for CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Encephalitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous IgG</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">MAYV</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">French Guiana, unknown date [<xref rid="B45-viruses-17-00261" ref-type="bibr">45</xref>] </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47, M</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Confusion</p></list-item><list-item><p>Phonophotophobia</p></list-item><list-item><p>Kernig and Brudzinski positive</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IgM MAYV seroconversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Meningo-encephalitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown,<break/>Recovered</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">RRV</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Papua New Guinea, 1980 [<xref rid="B46-viruses-17-00261" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27, M</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Polymorphonuclear leucocyte response in CSF</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum RRV antibody titer positive 7 dpa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute encephalitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Died</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Australia, 1993 [<xref rid="B33-viruses-17-00261" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40, M</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Head and neck stiffness</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum positive for anti-RRV IgM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Possible meningitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown,<break/>Partial recovery</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Central Australia, 1997 [<xref rid="B47-viruses-17-00261" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33, M</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Confusion</p></list-item><list-item><p>Personality changes</p></list-item><list-item><p>Speech difficulties</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum positive for anti-RRV IgM 8 dpa and IgG 90 dpa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral meningo-encephalitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Acyclovir</p></list-item><list-item><p>Ceftriaxone</p></list-item><list-item><p>phenytoin</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: chikungunya virus, CHIKV; immunoglobulin M, IgM; immunoglobulin G, IgG; Guillain&#x02013;Barr&#x000e9; syndrome, GBS; cerebrospinal fluid, CSF; real-time polymerase chain reaction, RT-PCR; non-steroidal anti-inflammatory drugs, NAIDS; Mayaro virus, MAYV; Ross River virus, RRV; days post-admission, dpa.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-00261-t002"><object-id pub-id-type="pii">viruses-17-00261-t002_Table 2</object-id><label>Table 2</label><caption><p>Countermeasures for neurological disease caused by Old World alphaviruses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Countermeasure</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Alphavirus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism/Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Status</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Prevention</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Attenuated vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV, evidence of cross reactivity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Attenuated nsP3 CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in US, CA, and EU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-viruses-17-00261" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Inactivated whole-virus vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RRV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Formalin- and UV inactivated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III trial completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-viruses-17-00261" ref-type="bibr">119</xref>]</td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1">Virus-Directed Treatments</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;3-methyltoxoflavin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits E2-E1 folding</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro studies completed</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B120-viruses-17-00261" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Chloroquine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SINV, SFV, CHIKV, MAYV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral uncoating and the type I interferon response </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No benefit in Phase II trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-viruses-17-00261" ref-type="bibr">121</xref>,<xref rid="B122-viruses-17-00261" ref-type="bibr">122</xref>,<xref rid="B123-viruses-17-00261" ref-type="bibr">123</xref>,<xref rid="B124-viruses-17-00261" ref-type="bibr">124</xref>,<xref rid="B125-viruses-17-00261" ref-type="bibr">125</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;CHIKV-265</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV, MAYV, ONNV, RRV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutralizing antibody targeting E2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-clinical studies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B126-viruses-17-00261" ref-type="bibr">126</xref>,<xref rid="B127-viruses-17-00261" ref-type="bibr">127</xref>,<xref rid="B128-viruses-17-00261" ref-type="bibr">128</xref>,<xref rid="B129-viruses-17-00261" ref-type="bibr">129</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;mRNA-1944</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Encodes human anti-CHIKV to elicit neutralizing antibodies </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I trial completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B130-viruses-17-00261" ref-type="bibr">130</xref>]</td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1">Host-Directed Treatments</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Supportive care</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pan-alphavirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydration, rest</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In Use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;NSAIDs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pan-alphavirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain reliever and fever reducer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In Use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Immunosuppressives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pan-alphavirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppress immune response to limit neuropathology</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In Use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-viruses-17-00261" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Intravenous IgG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pan-alphavirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppresses immune system to combat GBS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In Use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B131-viruses-17-00261" ref-type="bibr">131</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Plasmapheresis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pan-alphavirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Remove harmful antibodies involved in GBS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In Use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B131-viruses-17-00261" ref-type="bibr">131</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: chikungunya virus, CHIKV; non-structural protein 3, nsP3; Ross River virus, RRV; ultraviolet, UV; non-steroidal anti-inflammatory drugs, NAIDS; immunoglobulin G, IgG; Guillain&#x02013;Barr&#x000e9; syndrome, GBS; Sindbis virus, SINV; Semliki Forest virus, SFV; Mayaro virus, MAYV; O&#x02019;nyoug-nyoug virus, ONNV; messenger ribonucleic acid, mRNA.</p></fn></table-wrap-foot></table-wrap></floats-group></article>